We extracted 10191 term (phrases) from these articles.
These terms are noun phrases that have at least one mapping in the UMLS metathesaurus.
domain (a sub-domain of nuclear cardiology) to heuristically test the coverage of our ontology
terms.
Of these, we found 31 exactly matching terms, 2 morphological variants and 8 phrases that contained
the terms from the expert list.
Out of this 42 domain terms, 1 term, ‘dyperidamole’, was not found in our ontology (dyperidamole is
We found that this term didn’t exist in the 618 JNC abstracts we were using.
the 10191 retrieved terms and set that as our threshold.
We pruned the list to.
relationships and dependencies from data.
These techniques generally rely on a deep parse results that gives a rich representation which is
used for applications in knowledge extraction and semantics.
available to build models for efficient parsing on test data.
finite state automaton techniques.
UMLS graciously provides such a shallow parser[7] that is trained on entire Medline corpus and
claims to achieve over 97% accuracy.
9.  I plan to use the following privacy structure for my page (please check).
 Open public access to view and post  Open public access to view, with no ability to post 
__________________________________________.
I acknowledge that I will be solely responsible for managing the information and posts on my page.
Coordinator, administrator-level access to my page, group or account, to assist in case of
University must have an internship experience.
Your help in this matter is greatly appreciated.
Breast cancer incidence rates (in %) by stage at diagnosis from 2004 to 2011 for women who were
reported in [Iqbal et al, 2015].
Columns 3-10 correspond to the eight racial/ethnic groups identified therein.
between the member and non-member rate from their dues payment.
- Organizations that register 3 or more individuals may deduct $10 per registration from the total
due.
To receive discount, please make copies of this form and submit all registrations together listing
A cancellation fee of $30 per registration will be deducted for all refunds.
Use of recommended colorectal cancer screening tests can both detect cancer early, when treatment is
more effective, and pre- vent cancer, through the detection and removal of precancerous polyps.
However, in 2013, only 59% of adults 50 years of age and older reported receiving colorectal cancer
(removal of the rectum and all or part of the colon).
The majority of early stage (I and II) colon cancers are treated with colectomy alone (84%), while
most patients with stage III disease receive chemotherapy in addition to surgery (67%) (Figure 6,
page 11).
For rectal cancer, 61% of stage I patients have a proctectomy or proctocolectomy, about half of whom
In contrast to colon cancer, stage II and III rectal cancers are often treated with chemotherapy
possible.
A number of targeted drugs are also available to treat metastatic disease.
For patients undergoing surgery, an ostomy (creation of an abdominal opening, or stoma, for
elimination of body waste) may be needed.
created from the small intestine.
In many cases, once the colon or rectum heals,.
the stoma is closed and the ends of the large intestine recon- nected in a procedure called
Rectal cancer patients require a colostomy more often than colon cancer patients (29% versus 12%,
respectively).82 A permanent colos- tomy may be required if the anus and the sphincter muscle are
The 5- and 10-year relative survival rates for colorectal cancer are 65% and 58%, respectively.
When colorectal cancer is detected at an early stage, the 5-year survival rate is 90% (Figure 5,
page 9); however, only 39% of cases are diagnosed at this stage (Figure 4, page 8), in part due to
the underuse of screening.
Long-term survivors of colorectal cancer report a good overall quality of life compared with that of
the general population, but higher rates of depression.83 In addition, some difficulty with chronic
survivors, especially those treated with pelvic radiation.85, 86 In addition, survivors may suffer
from bladder dysfunction, sexual dysfunction, and negative body image.40, 87 Many of these issues
are more common in rectal cancer survi- vors, particularly those with a colostomy.88 A trained
colostomy care, such as skin irrita- tion and dietary considerations.89.
In the last few years there has been more research devoted to CAM.
However, there still remain many obstacles for CAM to be integrated into cancer treatment,
The lack of resources (plants) to produce these herbal remedies could result in inadequate supply
Another obstacle is the lack of.
In: The Richard and Hinda Rosenthal Lectures 2001.  The National Academies Press 26.  2.
Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, et al.
(2005) Use of complementary and alternative medicine in cancer patients: a European survey.
Metz J, Jones H, Devine P, Hahn S, Glatstein E (2001) Cancer patients use unconventional medical
Schofield PE, Juraskova I, Butow PN (2003) How oncologists discuss complementary therapy use with
Support Care Cancer 11: 348-355.  5.
Newell S, Sanson-Fisher RW (2000) Australian oncologists' self-reported knowledge and attitudes
about non-traditional therapies used by cancer patients.
the other two strengths.
Table 11.  Strength prediction results using different feature sets.
Feature notations: 1--Penn Treebank based Unigram), 2- -unigrams with WordNet based POS correction,
3--Binary semantics-based features), 4--K-ary semantics-based features, 5--unary semantics based
The standard error is that of the overall accuracy.
strength of relationships extracted from biomedical abstracts.
In addition to the conventional syntactic features such as unigrams and bigrams, we have also
explored and constructed semantics-based sequential features.
A wrapper-based method is then used to select the optimal feature sets for both polarity and
strength prediction.
Specifically, a multi-stage SVM classifier and an SVR predictor are built for polarity and strength
prediction, respectively.
Two different schemas, namely, (1 vs.  all) and (2 vs.
2), are employed to build the multi-stage SVM.
Finally, three different kernel functions are considered at different stage of this SVM classifier.
2) schema in general works better than the (1 vs.  all).
structures (KSS) are used, with a standard error ranging between 0.01~0.02.
strength analysis.
We are currently expanding our annotated corpus to facilitate further validation of the findings
We are also integrating this module with other modules as shown in Figure 1 towards building a
quantitative food-disease-gene network.
Finally, we are creating an interactive user interface to visually present this network.
This work is partially supported by the Mini Grant from the Center for Computing for Life Sciences
helping annotate the corpus and providing constructive suggestions and comments during this study.
[1] A.  M.
abstracts", BMC Bioinformatics 2005 (in press).
Extraction of biological interaction networks from scientific literature.
Briefings in Bioinformatics, (6)3:263--276, 2005.
[4] B.  Pang, L.  Lee, and S.  Vaithyanathan, "Thumbs up.
Sentiment classification using machine learning techniques," in Proceedings of the Conference on
Empirical Methods in Natural Language Processing (EMNLP), pp.
Yu et al., "GENIES: A natural- language processing system for the extraction of molecular pathways
from journal articles", Bioinformatics (2001), Vol.
Semi-automatic indexing of full text biomedical articles.
In AMIA Annu Symp Proc, pages 271{275, Lister Hill National Center for Biomedical Communications,
National Library of Medicine, Bethesda, MD 20894, USA., 2005.
[7] DR Swanson, Fish oil, Raynaud’s syndrome, and undiscovered public knowledge, Perspect.  Bio.
Med, v30, pp.  7-18, 1986.
3 (2003) , S.  1157-1182 .  [16] J.  A.  Mitchell, A.  R.Aronson, J.  G.Mork, L.  C.  Folk , S.  M.
Humphrey , J.  M.
Ward, "Gene indexing: Characterization and analysis of NLM’s GeneRIFs", Proceedings of the AMIA
Symposium 2003, 8th-12th November, Washington, DC, pp.
460-464.
de Identidade nº ____________________, voluntário ao PS-SMV-OF/ , foi por mim examinado e
previsto no respectivo Aviso, que consta de nadar o percurso de 25 (vinte e cinco) metros no tempo
máximo de 50 (cinquenta) segundos para o sexo masculino e 1 (um) minuto para o sexo feminino e
correr o percurso de 2.400 (dois mil e quatrocentos) metros no tempo máximo de 16 (dezesseis)
minutos para o sexo masculino e 17 (dezessete) minutos para o sexo feminino.
Arthur Pesquisa 53.776.609-1 2016.
National University is pleased to offer a Tuition Scholarship to university partners and their
employees, in addition to spouses and dependents if included in the partnership agreement.
To become eligible, you must be admitted in accordance with National University’s existing admission
requirements and processes for undergraduate- and graduate-level programs and/or coursework, and be
verification that your spouse or parent is a current employee (sponsor employee) of the contracted
university partner by providing a letter of verification from your sponsored employee.
Discounts and eligibility vary by organization, and not all degree programs and certificates are
University/National University System reserves the right to request additional documentation above
and beyond what is listed in this form, in order to verify eligibility at any time.
corporate benefits.
start date, course names, and period of attendance.
student.
communicate with your related third-party organization(s).
hospital by that provider’s EMS crew subsequently tests positive for the SARS-CoV-2 (COVID-19)
virus.
This is a change from the previous 12-hour notification requirement.
Notification of a positive test result is required regardless of whether CDC’s recommended use of
personal protective equipment (PPE) during transport of any individual with suspected or confirmed
COVID-19 was observed.
Notification shall not include the name of the patient who tested positive.
• Section 6.08 (a) - Every hospital shall provide notification as required in this Section to police
officers, firefighters, emergency medical technicians, private emergency medical services providers,
care, or life support services to a patient who has been diagnosed as having a dangerous
confidential medical record.
a confirmed diagnosis of any of the bloodborne communicable diseases listed by the Department
pursuant to subsection (b).
the police officers, firefighters, emergency medical technicians, private emergency medical services
General recommendations are: the steel angles should be at least 1/4 in.
(6A mm) thick; the horizontal leg should be at least 3-1/2 in.  (89 mm) for use with nominal 4 in.
The minimum required bearing length on each end of the fireplace opening is 4 in.  (100 mm).
Steel angle lintels should have a space at their ends to permit thermal expansion.
Combustion Chamber.
requirements and the amount of heat reflected and radiated into the room.
Figure 1 illustrates the shape and Table 1 provides recommended dimensions for the combustion
chamber.
These dimensions may be varied slightly, but the information given is based on successful designs.
The sides and lower portion of the back of the combustion chamber should be vertical.
Above the vertical portion of the back, the brick should be sloped forward towards the fireplace
opening to support the metal damper and the clay flue lining.
For the maximum amount of reflected heat into the room, the sloped portion of the back should be
plane rather than concave.
If it is concave, more heat will be reflected back into the fire rather than into the room.
Greater splay of the sides also increases the amount of heat reflected into the room.
be reduced.
combustion chamber to ensure that this air space is maintained.
(100 mm) in thickness around the back of the combustion chamber to support the loads from the smoke
chamber and chimney above.
Throat.
The throat is a slot-like opening directly above the top of the firebox through which flames, smoke
Because of its effect on draft, the throat of the fireplace should be carefully designed.
It should be a minimum of 8 in.  (200 mm) above the highest point of the fireplace opening.
Cast refractory and formed clay throats are available, built to certain angles and dimensions to fit
most conventional fireplace dimensions.
These elements are positioned on top of the firebox walls and eliminate the need of constructing
brick courses to form the throat.
Once in place, brick masonry can be built around the throat to give the appearance of conventionally
built throats in the breastwork of the fireplace.
Damper-The damper closes the fireplace opening to exterior air infiltration and can be used to
control the burning rate of the fireplace.
If you need to cancel an exam after you have registered, you must contact both the ACF office and
Host sites may charge an additional fee that is payable to the test site administrator hosting the
Contact the test administrator to confirm test time, host site fee and other specifics about the
additional principal and/or escrow that you may select.
interest rate (if applicable), Trustmark will notify you in writing before the change occurs and
will automatically adjust the monthly debit amount for you.
at least 15 days prior to next draft date.
This draft authorization will continue for the life of the loan or until I/We revoke this
Upon successful enrollment in the ACH program, you will receive a written confirmation letter via
mail or email.
I authorize Rebecca Farinas, M.D., LLC to charge this credit/debit/HSA debit card for any and all
co- payments, patient responsibility portions of my insurance explanations of benefits (if
prescription refills, and missed/no-show or late appointment fees.
hereby waive, release, and forever discharge the U.S.
employees, representatives, and volunteers, and their respective successors, assigns, heirs, and
personal representatives (each an “Indemnified Party”) from and against any and all claims, cost,
liabilities, damages, obligations, expenses, losses, or judgments, including reasonable attorney
fees and court costs (herein collectively “Claims”), arising out of or by reason of any activities
Fund for UNICEF and each Indemnified Party from and against any and all such Claims by third parties
participation in the Screening Activities, including without limitation any and all such Claims by
My Child upon reaching the age of majority.
Conta Hospitalar incluindo: material, medicamentos, período de internação, principais
intercorrências.
3.
Recibos de Honorários de Médicos, Auxiliares, Anestesistas, outros, devidamente assinados e com
4.  O Reembolso de internação só será autorizado nas localidades onde não exista rede credenciada.
We report the results for four experiments in this pa- per: i) the results of using the IDF stoplist
over a ba- sic stoplist, ii) the results of our approach using dif- ferent context descriptions of
the possible concepts of a target word, iii) the results of our approach com- pared to SenseClusters
using the con(cid:3)ated dataset.
The results of using an individualized IDF stoplist for each target word show an improvement over
us- ing the basic stoplist.
the large differences in accuracy makes it unclear which of the context descriptions performed the
On the con(cid:3)ated dataset, adding the ST de(cid:2)nition to the context description improved.
When analyzing the data, we found that there does not exist a CUI de(cid:2)nition for a large number
of pos- sible concepts.
Table 5 shows the number of words in the CUI and ST de(cid:2)nitions for each concept in the NLM-WSD
dataset.
The CUI de(cid:2)nitions in the UMLS come from a va- riety of sources and there may exist more than
one de(cid:2)nition per source.
The ST de(cid:2)nitions come from the same source and are approximately the same length but they are
a broad categorization.
We believe this makes them too coarse grained to provide descriptive enough in- formation about
To participate in the Sexual Health Education classes this 2016-17 school year offers.
I understand there will be no penalty for opting out of these classes.
I also understand that if I have any questions, comments, or concerns, I can reach Mr.
Batorowicz and Mr.  Zepeda at pbatorowicz@cps.edu​ and ​lmzepeda1@cps.edu.
In the event of your death, your heirs must satisfy the lien before they can acquire clear title.
Read the instructions on the back carefully before completing this application.
recorded and any unsatisfied liens or judgments (sometimes referred to as an “owners and
The report must be dated within 30 days of your application.
Stabilization of temperature T in the friction zone for all sam- ples comes in the range of 8
minutes.
(for Kocetal GF705) up to 40 minutes (Nylon 66) (Fig.  8).
9 We have developed meth- ods for heat treatment in oils, which make it impossible to hy- groscopic
Por tal razão, declaro estar ciente de que o atendimento via teleconsulta foi escolhido por mim, em
Covid-19, e expresso o meu consentimento para realização da consulta em questão.
In accordance with the Elementary and Secondary Education Act, Section IIII(h)(6) PARENTS’ RIGHT TO
KNOW, this is a notification from Ignite Achievement Academy to every parent of a student in a Title
professional qualifications of your student’s classroom teachers.
suggested that the college offer more workshops and 40 % suggested offer multiple times as well.
In terms of topics that student participants suggested, they included mentors’ research activities
on campus (41.7%) and career choices and opportunities (33.3%) and other topics.
Em caso de emissão de carteira provisória será necessário apresentar 02 fotos.  2.
Nos processos que envolva emissão de carteira, protocolados online, após a análise do processo, o
original deste RG também deve ser apresentado em uma das unidades do CREA-GO, conforme item 1 acima,
com exceção dos processos de segunda via de carteira.
estgrowthaftertheexpirationofpatentsonmanywidelyusedmedi-
increaseagain,punctuatedbyseveralhigh-profileexamplesofvery
costlynewagentsandsharpincreasesinthepricesofsomeolder ones.1
Between2013and2015,netspendingonprescriptiondrugs increasedapproximately20%intheUnitedStates,2
advent of the Medi- care drug benefit in 2006, government entities have paid for ap- proximately 40%
of the nation’s total retail prescription drug expenditure.6
Certainexpensivedrugproductsareimportantclini- cal breakthroughs and may even be relatively
cost-effective; oth- ersaremerelycostly,withpricesthataredifficulttojustifyinrela-
tiontotheiractualcontributionstopatientoutcomes.
TheUnitedStateshaslongspentmoreonprescriptionmedi- cationsthanothercountries.7
In2013,percapitaspendingonpre- scriptiondrugswas$858comparedwithanaverageof$400for19
advancedindustrializednations(Figure1).8 Listpricesforthetop
20highest-revenue-grossingdrugswereonaverage3timesgreater intheUnitedStatesthantheUnitedKingdom.9
(“rebates”) that manufacturers offer to US pay-
were10%to15%higherintheUnitedStatesthaninCanada,France, andGermany(Table1).11 In addition to their
paymentsfortheirmedications,suchincreasescanreducetheaf-
fordabilityofprescribedregimensandthuspatientadherence,lead- ingtonegativehealthoutcomes.12
However,somecostlydrugsmay offerreasonablevalue.Forexample,sofosbuvir(Sovaldi)wasfound
tobeacost-effectivetreatmentofhepatitisCinfectionevenatits 2013 launch price of $84000 per 12-week
course in certain pa- tientpopulationswhenviewedfromapatient’slifetimehorizonand a societal
perspective.13 Payers must pay for this treatment up-
front,though,withhealthcarebenefitsoftenaccruingdecadeslater.
visando recuperar a melhor função visual possível com a melhora estética.
A anestesia costuma ser geral realizada por anestesiologista especialista.
Em alguns casos o médico pode optar pela local que também será assistida por um médico
a primeira de outras cirurgias que poderão ser necessárias.
É uma cirurgia com índices altos de complicações se comparada com as cirurgias eletivas.
Podem ocorrer:.
Cicatriz corneana; f) Aumento da pressão ocular (Glaucoma); g) Catarata; h) Deslocamento de retina;
i) Estrabismo; j) Visão dupla; k) Flacidez ou irregularidade das pálpebras; l) Atrofia do nervo
óptico; m) Perda parcial ou total da visão; n) Atrofia e perda do globo ocular.
As chances de melhora e os riscos de complicações variam de acordo com a lesão, tempo de evolução,
presença ou não de alterações oculares prévias e/ou alterações sistêmicas concomi- tantes.
A indicação da cirurgia é de decisão do médico examinador que vê a possibilidade de oferecer um
Summary of C57BL/6 mice infected with GFP-expressing P.
berghei sporozoites and treated with metformin, primaquine, and mefloquine, alone or in combination
as described in Figures 1 and 3.
Prepatency was determined by detecting the presence of GFP+ red blood cells via flow cytometry
analysis.
The number of mice alive on day 10 is also shown.
In conclusion, metformin treatment in combi- nation with suboptimal dosage of conventional
antimalarials is more efficacious in reducing parasite load.
Metformin is listed by the World Health Organization as an essential medicine to treat and prevent
type 2 diabetes.
goat’s rue (Galega officionalis).
This medicinal plant was traditionally used in medieval Europe as a treat- ment for diabetes and
Metformin was first synthesized in 1922, but its use as an antidiabetic agent was only proposed in
proguanil, a highly potent antimalarial biguanide.
In the 1940s, metformin was tested in patients with an ongoing malaria blood stage infection while a
search was underway for alternatives to proguanil, which was becoming ineffective because of
parasite resistance (34, 37).
Although no clear effect on parasitemia was found (34), lowered glucose levels were later noticed
Indeed, the antihyperglycemia property appears to be common to most biguanides, but metformin
safety profile and few interactions with other medications.
and accessible (37, 38).
These properties contribute to metformin’s qualifications as an optimal drug for repurposing (39).
observations and meta-analyses demonstrating positive outcomes and improved prognosis in diabetes
patients diagnosed with cancer.
(25, 42) and AIDS (43).
from the liver and increase circulating insulin sensitivity.
This leads to a decrease in oxidative phosphorylation and subsequent drop in energy with altered
ADP-to-ATP ratios (22, 44, 45).
AMPK and a shutdown in gluconeogenesis (46–48).
AMPK-dependent processes that are altered include suppression of mTOR and insulin receptor signaling
(IGF-I) via PI3K/AKT pathways, leading to decreased protein synthesis and cell growth and increased
Other mechanisms independent of.
REPRESENTANTE LEGAL, sem rasuras, para correta análise do seu pedido de indenização.
regularizada, ativa, desbloqueada e sem impedimento para o crédito de indenização/reembolso.
Apenas o Representante Legal precisará assinar o formulário (no campo 2- “Assinatura do
Beneficiário com 16 ou 17 anos - Necessário que o Beneficiário seja assistido por seu “Representante
Legal” (Pai, Mãe, Tutor).
Necessário que o formulário seja assinado pelo menor de idade (no campo 1 “Assinatura do
Declaro que os dados bancários são de minha titularidade e, comprovada a cobertura securitária para
o sinistro, autorizo a Seguradora Líder a efetuar o pagamento da indenização do Seguro DPVAT,
mediante o crédito na referida agência e conta.
Após efetivado o crédito, reconheço e dou plena quitação do valor indenizado.
along the supply and distribution chains.
ex- manufacturer price), based on one or a combination of the following broad structures:.
In order to protect our customers from unauthorized usage of their credit cards, if you would like
us to bill charges to a credit card not physically presented to us at check in, please fill out the
following and fax this form back (614) 416-8444.
This form must be filled out in its entirety in order for us to bill a credit card not physically
presented.
In accordance with 28 CFR Section 16.41(d) personal data sufficient to identify the individuals
submitting requests by mail under the Privacy Act of 1974, 5 U.S.C.
Section 552a, is required.
Section 1001 and/or 5 U.S.C.  Section 552a(i)(3).
20503.
is true and correct, and that I am the perso n named above, and I understand that any falsification
Section 1001 by a fine of not more than $10,000 or by imprisonment of not more than five years or
both, and that requesting or obtaining any record(s) under false pretenses is punishable under the
provisions of 5 U.S.C.
552a(i)(3) by a fine of not more than $5,000.
Section 552a(a)(2).
Requests will be processed as Freedom of Informat ion Act requests pursuantto 5 U.S.C.
Section552,rather thanPrivacy Act requests,forindividuals who are notUnited States citizens or
3 Providing your social security number is voluntary.
You are asked to provide your social security number only to facilitate t he identification of
records relating to you.
Without your social security number, the Department may be unable to locate any or all records
pertaining to you.
realização do serviço Founda�onOne e suas respec�vas implica- ções sejam perfeitamente esclarecidas
e compreendidas por você.
Este documento é um Termo de Consen�mento.
Assim, por favor, leia atentamente, discuta e �re todas as suas dúvidas com o médico que lhe
recomendou/-solici- tou este serviço antes de assiná-lo.
A decisão de contratar ou não este serviço é sua.
Este documento deve ser completamente preenchido e assinado por você e/ou por seu representante
O Serviço Founda�onOne é realizado pela empresa Founda�on Medicine, Inc., comercializado e operado
pela Roche Brasil e foi recomendado/solicitado pelo seu médico (conforme indicado no início deste
formulário).
palavras, criar/transcrever um “RG” do seu tumor), observar as alterações específicas que este pode
possuir e iden�ficar, com base em banco de dados disponível no momento da realização do serviço, as
opções existentes de tratamento para seu caso e/ou pesquisas clínicas em andamento, para as quais
você tenha perfil para solicitar par�cipação ao respec�vo patrocina- dor.
Estas informações, portanto, serão avaliadas por seu médico e poderão auxiliá-lo na escolha do
melhor tratamento disponível para tratar seu câncer ou ainda na eventual indicação por seu médico
para par�cipar de pesquisas clínicas em andamento, que possam lhe trazer bene�cios, caso seja de sua
vontade e escolha.
Mais detalhes sobre este serviço podem ser encontrados no site www.founda�onmedicine.com.br.
Uma amostra do seu tecido tumoral será enviada, por intermédio do laboratório DB – MEDICINA
DIAGNÓSTICA LTDA., ao laboratório da Founda�on Medicine, Inc.
re�rada em alguma cirurgia ou biópsia que realizou.
lhe dará as orientações para coleta da amostra (obs.
Eventuais custos para coleta da amostra não estão inclusos no valor do serviço, sendo de inteira
responsabilidade do paciente).
documento caso obtenha todas as informações) sobre todo o cuidado requerido no manejo, armazenamento
e transporte de material biológico.
laboratório da Founda�on Medicine, Inc.), enviará ao seu médico um relatório (em inglês) detalhado
pesquisas clínicas relacionadas que estejam em andamento em todo o mundo.
Após 10 (dez) dias do recebimento do relatório (em inglês) por seu médico, você receberá o seu
relatório completo com primeira e úl�ma páginas traduzidas para o português.
são melhores para seu tratamento.
auxiliá-lo/encaminhá-lo/indica-lo aos centros de pesquisas/patrocinadores/pesquisadores que sejam
responsáveis pela condução das pesquisas clínicas indicadas no relatório.
as quais você tenha perfil para solicitar par�cipação, não implica no fato de que sua par�cipação
será aceita pelos responsáveis pela condução da pesquisa clínica, não possuindo a Founda�on
e a Roche Brasil qualquer responsabilidade neste sen�do.
Ainda, a decisão final, de seguir ou não com o tratamento ou sugestão de seu médico, é sua.
informações e exclarecimentos con�dos neste documento, me explicou detalhadamente os riscos e
outra informação ou esclarecimento.
1.690, compete aos pais, e na falta de um deles ao outro, com exclusividade, representar os filhos
sendo estes julgados ausentes, ou em caso de os pais decaírem do poder familiar, compe�rá ao tutor
legal representar o menor até os dezesseis anos e assis�-lo após essa idade - Código Civil
Brasileiro Art.
1.747).
Já, caso o paciente seja maior de 16 e menor de 18, tanto o representante legal, quanto o paciente,
deverão assinar este termo (“assistência”).
•Em casos de pacientes maiores de idade, mas que não possam por causa transitória ou permanente
manifestar sua vontade, de acordo com o Código Civil Brasilei- ro, estas pessoas devem ser
1767, I, CC).  Data de assinatura: _______/_______/________.
•Representante Legal: É aquele que por lei ou declaração judicial está autorizado a contrair
De acordo com o Código Civil Brasileiro Art.
1.690, compete aos pais, e na falta de um deles ao outro, com exclusividade, representar os filhos
sendo estes julgados ausentes, ou em caso de os pais decaírem do poder familiar, compe�rá ao tutor
legal representar o menor até os dezesseis anos e assis�-lo após essa idade - Código Civil
Brasileiro Art.
1.747).
Dessa maneira, no caso de um paciente menor, caso este seja menor de 16 anos, apenas o representante
deverá assinar este termo (“representação”).
manifestar sua vontade, de acordo com o Código Civil Brasileiro, estas pessoas devem ser
representadas por seu curador, nos termos da lei civil (art.
Profit control is an effective measure to manage medicine prices insofar as the regulators have
Typically, this means that the regulator needs to have full visibility of the supply and
The regulator also needs to have the capacity and ability to enforce non-compliance.
provision of medicines.
In contrast, it may be much less effective in health care settings where the private sector plays a
significant role in the delivery of medicines, or where the structure of supply chain is complex or
under-developed (183).
there is a justification.
(185).
information about the prices and sales of their patented drug products in Canada at introduction and
The Board considers the average price of specific strength and dosage of a medicine to assess if a
product is priced excessively according to the following criteria (186):.
The originator company may file a Voluntary Compliance Undertaking to express its commitment to
adjusting the price of the patented medicine in question to a non-excessive level and offsetting any
excess revenues, in compliance to the Board’s guidelines.
OOP costs in the year of diagnosis came mostly from professional and non-inpatient facility
Figure 8 shows the level of OOP costs by percentile for all study cancers combined.
In general, patient cost-sharing is higher for out-of-network services than in-network.
portion of OOP costs for out- of-network providers; conversely, patients in the lowest decile
specialty care center that may be out of network, the lack of network providers with appropriate
working at an in-network hospital (e.g., radiologist, assistant surgeon, anesthesiologist).22 23
Figure 9 suggests that there might be significant financial consequences to the patient going out of
network, which could be exacerbated if health plans remove popular cancer providers from their
networks.
axis--relative to total spending) and total patient cost-sharing (left vertical axis).
While most patients in our study reported under 10% of all OOP cost in the year of diagnosis is
The electronic media record of my transactions and facsimile of this authorization form held by AF
shall be used as the final determination to resolve any disputes that I may have regarding
transactions authorized herein.
De acordo com o Item 3.1 do Edital de Processo Seletivo 001/2018 do Município de Paial (SC),
37, VIII da Constituição Federal e Lei n.° 7.853 de 24 de outubro de 1989, venho requerer reserva de
vaga a candidato portador de deficiência, apresentando laudo médico com CID em anexo, conforme
Firstly, as indicated by a widely-cited study by a global consulting firm, increasing price would
generate larger improvement in profit than other levers of profit (Fig.
3.7, p.31) (150).
This may have influenced repeated price increases noted in the market for cancer medicines (147,151)
Secondly, as there are many factors influencing demand of medicines other than price (50), it would
been said “price is certainty and volume is a bet”.
infusion [32,33], or cholecystokinin tetrapeptide (CCK-4) injection [32,34].
These chemical exposures are used as potent tools to design controlled studies with predictable
levels of PA episodes.
In a study with healthy volunteer subjects using carbon dioxide inhalation to provoke panic and
anxiety, propranolol significantly decreased heart rate, a cardiovascular somatic symptom, but did
not provide psychic anxiolytic benefit [35].
Subsequent reports have also echoed that propranolol might be effective for this condition [38-40],
When considered in aggregate these clinical studies of propranolol, as the well known prototypical
beta blocker, provide convincing evidence that the drug can exert somatic (i.e., peripheral) effects
With regard to affecting the psychic (CNS) symptoms, the results have been negative, inconsistent,
That being said, there is some limited evidence that propranolol can exert some psychic (CNS)
Thus, propranolol enhanced cognitive flexibility (“creativity”) during stress.
symptoms.
Notable among these is the common drug, atenolol, that is available in oral solid dose forms ranging
Multiple doses per day may be permitted.
Thus, atenolol might be preferred over the nonselective beta blockers for patients affected by
~ 10 bpm on placebo [46].  Also,.
It does not pass through the blood-brain barrier.
performance related to tremor [48].
A similar result was obtained for nadolol in students’ singing performance [49].
patients based upon the appropriate dosage, an anti-intuitive result [50].
An alternative beta blocker is pindolol, a non-selective agent, which can enhance the effects of
Pindolol reduced symptoms of performance anxiety in musicians [51].
Another example is betaxolol that can also cross the blood- brain barrier.
Daily oral betaxalol was delivered at 5 - 40 mg per day in the treatment of generalized anxiety
disorder and other anxiety-related conditions.
Anxiety and panic attacks were reduced within several days [52].
that beta blockers can provide some symptomatic relief with regard to performance anxiety [53].
However, beta blockers alone do not sufficiently address the aggregate symptoms of panic and acute
anxiety episodes, and especially the psychic symptoms thereof (e.g., fear, avoidance, and
anxiousness).
Beta blockers also exhibit some benefit with regard to alcohol and drug abuse.
The abuse of alcohol, prescription drugs, and illegal drugs (e.g., opioids, opiates, and cocaine)
The symptoms of sudden withdrawal depend upon the abused substance, the impairment of neurological
The withdrawal from addictive substances produces an array of symptoms, many of which overlap with
Delirium tremens (DTs) occur in some alcoholics upon abrupt cessation of drinking.
The symptoms of alcohol-related DTs are very similar to those of panic attacks, and are in part
The standards-of-care for DTs are oral benzodiazepines.
Withdrawal from opioid and/or opiate addiction is physiologically distinct from alcohol withdrawal.
trials to be beneficial in alcohol withdrawal [54-56].
60].
Note that propranolol has also been shown to suppress tremors [61], consistent with one of the
monoplegia, monoparesia, tetraplegia, tetraparesia, triplegia, triparesia, hemiplegia, hemiparesia,
ostomia, amputação ou ausência de membro, paralisia cerebral, nanismo, membros com deformidade
olho, com a melhor correção óptica; a baixa visão, que significa acuidade visual entre 0,3 e 0,05 no
anteriores;.
Nevertheless, underrepresented minority students should not be discouraged from applying to
These statistics are simply statistics and do not in any way reflect bias against minorities within
the osteopathic medical profession.
progressively younger every year.
In 2012, it was 25 years old, not much older than the average age of MD school matriculants in the
same year, which was 24.22, 23 If becoming a physician is your goal, the statistics and information
provided above should be enough to show that there are indeed two similar, legitimate paths you can
As we have also pointed out, however, there are several fundamental differences between allopathic
1.  2012 Osteopathic Medical Profession Report.  In American Osteopathic Association.
Documents/2012-OMP-report.pdf.
2.  What is osteopathic medicine.  In American Association of Colleges of Osteopathic Medicine.
Retrieved August 6, 2011, from http://www.aacom.org/about/osteomed/Pages/default.aspx.  3.
Croasdale, Myrle.  (2003, June 16).  Can-DO strategy: Osteopathic medicine survives, and thrives.
Vaccination News.
Retrieved from www.vaccinationnews.org/DailyNews/2003/June/08/Can- DOStrategyOsteopathic8.htm.
4.  American Association of Colleges of Osteopathic Medicine.  (2010).
Introduction to osteopathic medicine for non-DO faculty: What makes osteopathic education different.
[PowerPoint slides].
Retrieved from http://data.aacom.org/education/ECOP/down- load_nonDOfaculty.asp.  5.
aacom.org/docs/default-source/data-and-trends/fall-2014-pre-
liminary-enrollment-report-fast-facts.pdf?sfvrsn=8.
Career and Community Leaders of America (FCCLA) with regard to social media use.
Wirth.
 I will keep the other State Executive Council members accountable for their actions on social
media by use of private messaging and in connection with state staff.
We train logistic regres- sion with the same train-test split (days 1-277, days 278- 365).
Although many of the positive feature are sensi- ble and similar to those found in the ranking
2016), we find that the negative features are dominated by alzheimers and dementia related terms in
the title and abstract.
These results are indicative of an oddity in the dataset provided by Altmetric, specifically the
web- site Alzforum.
included in Altmetric’s news crawl.
marked as a non-news source due to its super high rate of publication.
Before sampling, Alzforum covers 8,347 of the 34,329 scientific articles with no real coverage and
However, it covers only 667 of the 57,668 scientific articles with real coverage.
Of 8,436 matched pairs, Alzforum cov- ers 1,380 negative and 224 positive samples.
Although we control for subjects, they are typically more general, such as “neuroscience,”
control for specific topics, such as alzheimers, and logistic regres- sion learns that most
alzheimers articles are unpopular.
Similar to the ranking experiments, we repeat the matched sample experiment on the subset of
We find 3,398 matched pairs and confirm that the positive and negative instances do not have dispro-
Using all features, logistic regression achieves an F1 of 0.5794.
Table 7 lists the top features for these results.
Top negative features ap- pear to be those related to more technical scientific work, such as
“proteins” and “genes” “expression”, while positive features are related to health, such as “fat,”
“screening,” and “Project HOPE,” a publisher of health policy articles.
feature when occurring in the title.
disciplines, universities, jour- nals, and news outlets.
ranking one.
We find the most important feature to be whether the scientific article has a press release
published.
You have been authorized to receive one or more private and public key pairs and associated
certificates.
A private key enables you to digitally sign documents and messages and identify yourself to gain
access to systems.
You may have another private key to decrypt data such as encrypted messages.
private keys to verify your digital signature, or to verify your identity when you attempt to
The certificates and private keys will be issued on a token, for example a Common Access Card (CAC),
The certificates and private keys on your token are government property and may be used for official
the key recovery process, or a Certification Authority's (CA's) determination to terminate or revoke
a certificate.
eSecuritel considers material misrepresentation of facts regarding your claim as an act of Fraud.
If eSecuritel determines the facts of your claim were intentionally misleading, eSecuritel reserves
the right to charge you the additional costs incurred by eSecuritel and will take legal action as
your child’s current proficiency level in English, the school’s recommendation for program
criteria.
side of this form.
To request that your child be assigned to an Alternative Program in which a significant amount of
instruction is provided in your child’s primary language, you must apply for a Parental Exception
Waiver.
Bank card payment (VISA, MasterCard, or American Express) is accepted for fees payable to the
Washington State Patrol.
Complete the following information and submit with the requisite forms for your request.
security code on any form other than this authorization form.
All information below must be complete in order to process your card.
Masonry Units.
respectively.
3 Series.
Concrete masonry units are usually used for the interior wythe of a cavity wall in combination with
a brick masonry exterior.
Hollow or solid concrete masonry units should conform to ASTM C 55 Specification for Concrete
Building Brick, ASTM C 90 Specification for Loadbearing Concrete Masonry Units or ASTM C 129
Non load- bearing concrete masonry units are usually specified for the interior wythe when the brick
and block cavity wall is used as infill walls for concrete or steel frame structural systems if
Structural clay tile has been used as a backing material for cavity wall construction.
Structural clay tile for this purpose should conform to ASTM C 126, ASTM C 34 Specification for
Structural Clay Load-Bearing Wall Tile or ASTM C 212 for Structural Clay Facing Tile.
Clay tile units under ASTM C 126 and ASTM C 212 are commonly used for the interior wythe of a cavity
wall when left exposed for architectural appearance reasons.
The strength and moisture penetration resistance of a brick masonry cavity wall are affected by the
mortar selection and compatibility with the brick units.
Portland cement-lime, mortar cement, or masonry cement mortars can be used.
However, mortars with an air content less than 12 percent are recommended for their superior bond
percent for assemblies constructed with masonry cement mortars or portland cement-lime mortars that
have air entrainment.
In addition, some building codes prohibit the use of masonry cement mortars and all Type N mortars
Mortar should meet the proportion requirements of ASTM C 270 Specification for Mortar for Unit
Masonry as shown in Table 1.
See Technical Notes 8 Series for more detailed information on mortar types and selection.
Note: ‘Pharmerging’ is a group of 21 countries with less than US$ 30 000 GDP per capita and greater
Arabia, Indonesia, Egypt, Philippines, Pakistan, Viet Nam, Bangladesh, Argentina, Algeria, Colombia,
South Africa, Chile, Nigeria, Kazakhstan.
European Union Five includes France, Germany, Italy, Spain and the United Kingdom of Great Britain
and Northern Ireland.
commentary from diverse stakeholders in recent years.
Stakeholders at all levels – from patients and clinicians to governments – have expressed their
medicines to patients, as well as the sustainability of health systems.
base and an ethos of very small benefit at whatever cost; rather, we need delivery of fair prices
and real value from new technologies” (28).
treatment was “not tenable” (29).
In 2013, a group of more than 100 experts in chronic myeloid leukaemia pointed to Stakeholders
the fact that 11 of the 12 medicines approved by the United States Food & Drug Administration (US
(31).
suitably resulted in outcomes that meet both policy and economic objectives, as well as public
disproportionally to the benefits conferred and to the extent that the financial sustainability of.
English proficiency (LEP).
and other measures.
Your child’s English proficiency test scores are shown below.
outlined in the attached document.
We believe that this program will help meet your child’s educational needs and enhance his/her
If your student currently has an Individualized Education Program (IEP), their needs will continue
You may withdraw your child from services at any time you desire.
You may also mark the appropriate box at the bottom of this form.
Please seriously consider the consequences of your decision on your child’s long-term educational
If you have questions, please call the school at 1.580.323.1800.
The preceding paper explains the process and evidence used to develop policies for the Journal of
Forecasting.
The policies are reflected in the “Guidelines for Authors” published on the back cover of this issue
(A complete Editorial manual is available from the editors.).
We feel that the Journal of Forecasting policies are ambitious.
likelihood of publication.
However, violations of these guidelines will not eliminate a paper as a candidate for publication.
We would not be so bold as to suggest these policies define the best procedures for all authors,
The policies should be an aid, not a restriction.
As you know, my office represents the City and County of San Francisco, including its Health Officer
Dr.
(See https://www.sfdph.org/dph/alerts/coronavirus-healthorders.asp.) Dr.
Aragón understands and respects the importance of religion to the spiritual well-being and mental
health of many, and accordingly has encouraged San Franciscans to continue to practice their
C19-07e, the “Health Order”), which allows for in-person outdoor services conducted according to
Unfortunately, and contrary to increasing medical evidence that religious services without
violate the Health Order and jeopardize the health and safety of San Franciscans.
Given the recent rise in cases and hospitalizations, Dr.
Aragón’s concerns about these risks have only been heightened.
More particularly, the City understands that Archbishop Cordileone informed all parishes and other
worship sites in the Archdiocese, including San Francisco, that they could resume public Mass on
Sunday, June 14, 2020.
the San Francisco Health Officer’s determination that indoor services with congregants continue to
pose a serious public health risk and are consequently prohibited under the Health Order for the
time being, with a narrow exception for funerals with 12 or fewer persons and an exception for live
streaming services with.
This article outlines a practical and efficient three-pass method for reading research papers.
I also de- scribe how to use this method to do a literature survey.
Categories and Subject Descriptors: A.1 [Introductory and Survey].
Researchers must read papers for several reasons: to re- view them for a conference or a class, to
A typi- cal researcher will likely spend hundreds of hours every year reading papers.
beginning and plow- ing your way to the end.
general idea about the paper.
The second pass lets you grasp the paper’s content, but not its details.
The third pass helps you understand the paper in depth.
1.  Category: What type of paper is this.  A measure- ment paper.  An analysis of an existing system.
A description of a research prototype.  2.  Context: Which other papers is it related to.
Which theoretical bases were used to analyze the problem.
Using this information, you may choose not to read fur- ther.
This could be because the paper doesn’t interest you, or you don’t know enough about the area to
The first pass is adequate for papers that aren’t in your research area, but may someday prove
Incidentally, when you write a paper, you can expect most reviewers (and readers) to make only one
abstracts.
If a reviewer cannot understand the gist after one pass, the paper will likely be rejected; if a
never be read.
The first pass is a quick scan to get a bird’s-eye view of the paper.
You can also decide whether you need to do any more passes.
Are results shown with error bars, so that conclusions are statistically sig- nificant.
I authorize The Peoria Chamber of Commerce to charge the amount listed above to the credit card
provided herein.
This is a one-time charge for use of the Peoria Chamber of Commerce Conference Room; there are no
I believe that my appeal/motion is valid, and I declare that the following information is true and
Under the Paperwork Reduction Act, a person is not required to respond to a collection of
information unless it displays a valid OMB control number.
impose the least possible burden on you to provide us with information.
The estimated average time to complete this form is one (1) hour.
Counsel, 5107 Leesburg Pike, Suite 2600, Falls Church, Virginia 22041.
The information on this form is requested to determine if you have established eligibility for the
EOIR may provide this information to other Government agencies.
Failure to provide this information may result in denial of your request.
Phone  number:                                         Fax  number:
Service
Diagnosis code (ICD-10):
Equipment/supply/service  needed, including HCPCS   codes:
Valid and appropriate clinical documentation (e.g., medical visit notes, therapy logs, prescriptions) must be
LOCAL  E DATA:  Rio de Janeiro       , em  05 de   02          de 20 19
by providing unparalleled medical care
OWNER’S        INFORMATION
Owner’s  Last Name:                                            First:                                          Middle:
Gordon                                                       Michael
Email Address:
mgordon@largo.com
585   Grove     St                                                             ( 231 ) 325-2735                  ( 231 ) 947-6921
Herndon                                               VA                          20170
Occupation:                            Employer:                                                                  Work  Phone:
Enginner                                AT   & T                                                                  ( 269   ) 763-9407
(cid:1) Yes (cid:1) No Wepfer                                         Megan                                       (  248  )  628-2538
Friend                                                            mwepfer@madeirabeachfl.gov
Emergency   Contact First Name                                   Emergency   Contact Last Name:              Emergency  Contact  Phone:
Aaron                                                           Diebold                                     (616)281-1323
HOW      DID   YOU     LEARN      ABOUT      OUR     HOSPITAL?
(cid:1) Yellow Pages
(cid:1) Yellow Book
Company:                                                               Job Title:
Company   Contact (Supervisor, HR Professional):
Signature of Employee/Student                                                Date:
TO:    Illinois EMS Medical Directors
Illinois Hospitals
FROM:  Ashley  Thoele, MSN,  MBA,  RN
Division Chief, EMS  and Highway  Safety
Drug  Name  (Brand  Name)                    Biomarker(s)                     Indication(s)
24      Dexlansoprazole  (Dexilant®)                 CYP2C19                          Heartburn, gastroesophageal
disease, and gastroesophageal
reflux disease
26      Lansoprazole  (Prevacid®)                    CYP2C19                          Peptic ulcer disease,
gastroesophageal  reflux disease
ride, potassium chloride, sodium ascorbate,
anemia
30      Methylene  blue (Provayblue)                 G6PD                             Methemoglobinemia
Immunology
31      Indacaterol (Arcapta®)                       UGT1A1                           COPD
34      Boceprevir  (Victrelis®)                     IFNL3                            Hepatitis C
35      Chloroquine  (Aralen®)                       G6PD                             Malaria
37      Isoniazid (Nydrazid®)                        NAT1;  NAT2                      Tuberculosis
39      Maraviroc  (Selzentry®)                      CCR5   receptor                  HIV
40      Nitrofurantoin (Furadantin®)                 G6PD                             Urinary tract infections
41      Peginterferon  alfa-2b (Pegasys®)            IL28B                            Hepatitis B, hepatitis C
42      Primaquine                                   G6PD                             Malaria
44      Quinine  sulfate                             G6PD;   CYP2D6;  CYP3A4          Malaria
45      Rifampin  (Rifadin®)                         NAT1;  NAT2                      Tuberculosis
46      Sulfamethox-azole  and trimethoprim          G6PD                             Bacterial infections
47      Telaprevir (Incivek®)                        IFNL3                            Hepatitis C
Please bill my:    Visa        MasterCard         Amex          Discover
Credit Card Number:                                   Exp Date:                 CSC   #:           Amount:
Name  on Account:                                                      Signature:
(Optional) I would like an additional $             debited each  month  and applied to my escrow  account.
Name  of Patient:   Trinh Crona                                   DOB:  03  06 1976
First Name  (as it appears on credit card): Marlin
Last Name  (as it appears on credit card): Bruen
Credit Card  Type:  Please Circle        Visa           MasterCard
Credit Card  Number:    371289649801032
Expiration Date:     03 01 2026
CCV   code:  448
Billing Address for Credit Card
Zip Code  85301
Signature of Parent/Guardian                      Signature of Parent/Guardian
5550  EAST  WOODMEN      RD
LORADO     SPGS   CO   80920
City/State/Zip                                    City/State/Zip
Date                                              Date
I – PARA USO DO SERVIDOR
48785                           Daniel Sarmento  de Freitas
DADOS BANCÁRIOS PARA DEPÓSITO
Banco:    Banco do Brasil      Agência:            Conta Corrente:  saving
MOTIVO DO REEMBOLSO:     DESPESAS HOSPITALARES COM EQUIPE CIRÚRGICA     EXAMES
EQUIPE CIRÚRGICA     CONSULTAS      ANESTESIA     REMOÇÕES      TRATAMENTOS
MOTIVO  DO REEMBOLSO:     DESPESAS HOSPITALARES COM EQUIPE CIRÚRGICA    EXAMES
PROCEDIMENTOS  AMBULATORIAIS      MATERIAL CIRÚRGICO     LENTE INTRAOCULAR
EQUIPE CIRÚRGICA      CONSULTAS     ANESTESIA      REMOÇÕES        LENTE INTRAOCULAR
CÓDIGO   DO PROCEDIMENTO                       VALOR  PAGO       VALOR  REEMBOLSADO
1-                           547749                       R$50,000            R$25,000
4-
5-
EM       / 01/01/19 /
Assinatura do Conferente
INTRODUCTION:  IT TAKES A CONSORTIUM                                       6
WHAT  IS TARGETED ONCOLOGY?                                                7
IS CANCER SPECIAL?                                                         9
RECENT SPENDING  TRENDS FOR TARGETED CANCER  DRUGS                         12
VALUE FRAMEWORKS                                                           15
INTERNATIONAL  DRUG PRICING                                                19
ORPHAN  DRUGS                                                             24
CONCLUSION                                                                26
Spouse’s  name                                              Social Security number            Date of birth
City                                                        State         Zip code            County
Last year’s total household income      Parcel ID number  from  tax statement   Year  property was purchased
Estimated  market  value (from Notice   Is property currently classified        Year  homestead   was established
of Real Estate Value or tax statement)  as homestead?
Legal description of property (or you can attach a copy of your deed)
here  Applicant’s signature                                                Date                   Daytime  phone
Account Type:         Saving  Account
Name  of Bank:        Bank  of America
Bank Routing Number:  301180056
Bank Address:         711  WEST   DOUGLAS,    Wichita, KS,67213  USA
Bank Branch Number:
ID Number(s) of Payee: 392 54 8534
Account  Holder                                         Account  Holder
Signature:                                              Signature:
Print Name:                                             Print Name:
Date:                                                   Date:
Strength of compression strength
Modulus  of elasticity E, MPa           1883,1              1743,9                 7,39
Nome  do(a) Paciente: Arthur Pesquisa                                      Data: 04 / 12  / 2005
Rafael
Nome  do(a) Profissional de Saúde :  Barbastefano
Sigla e número do Conselho de Classe Profissional : 55 98 98112-7250
-Pre-Workshop:
I am aware  of my own  needs, interests, goals, and strengths         4.28 (0.77)      138
-Post-Workshop:
I would like to build good habits to be a successful scientist.       4.59 (0.76)      133
The workshop   is helpful.                                            4.65 (0.70)      133
The workshop   is organized well.                                     4.73 (0.62)      133
Will attend future related workshops.                                 4.63 (0.70)      133
Pre-          Post-        Diff.                       d
Workshop      Workshop     (SE)
More  knowledge   and  skills to 3.56 (0.92)   4.39 (0.69)  0.827    9.72***    <.001   1.02
be a successful scientist                                   (0.98)   (132)
Able  to use  good  habits  and  3.62 (0.97)   4.35 (0.78)  0.729    8.47***    <.001   0.83
resources/  services/  facilities                           (0.88)   (130)
etc.
Overall confidence in becoming   3.13 (0.95)   4.20 (0.93)  1.070    11.61***   <.001   1.14
a successful scientist                                      (0.98)   (113)
Believe      mentoring      for  4.65 (0.75)   4.80 (0.57)  0.158    2.37*      .019    0.22
NOME                       Arthur  Pesquisa
RG                         53.776.609-1
CPF                        098237304-07
ENDEREÇO
Bairro: Maracana           Município:
TELEFONE                   +5598988578047
ESCOLA                     Federal  University of São  Paulo
(    )PÚBLICA                            (    )    PRIVADA
TURNO   DO  CURSO                    (   ) MANHÃ              (     ) TARDE
Insira no retângulo abaixo a assinatura que deseja que conste na carteira profissional.
Colar aqui Foto 3x4
fundo branco.
Declaro  serem verdadeiras as informações aqui prestadas. Estou ciente que a declaração falsa constitui crime previsto
Local e data:                            ,         /          /
Insira no retângulo abaixo a assinatura que deseja que conste na carteira profissional.
fundo branco.
Declaro  serem verdadeiras as informações aqui prestadas. Estou ciente que a declaração falsa constitui crime previsto
no Código  Penal Brasileiro e infração ao Código de Ética Profissional.
Local e data:                            ,         /          /
Assinatura do  Requerente   idêntica à do documento   de identificação apresentado   no processo
Last Name                                                   First Name                                           Middle
Street Address                                                                                       Apt/Unit
City                                                                                          State          Zip Code
Email                                                                              Phone
Satisfaction of all degree/certificate requirements as outlined in HCC catalog.
Successful completion  of current course work*:
Course                                                                    Pending  Sub
Completion  of this program requires credits to be moved as marked  on attached degree  audit
*Substitutions considered  approved  following signature by dean and VPAA
diploma/certificate and in the Commencement    program  as I’ve written above. I understand that receipt of my diploma is contingent upon satisfying all
financial obligations with Howard   Community   College.
Student Signature                                                                                      Date
Experimental   Arm          Control  Arm
No. Assigned   (to each
Percentage   of Males
Mean   Age
Percentage   Non-White
No. judged  non-
complete  the
intervention)
outcome   measure
•  Survival / All-
cause  mortality
•  Cancer  mortality
•  Primary  cancer
recurrence
•  Second   primary
•  Quality of life
•  Side  effects
Table1.ExamplesofCountry-SpecificAverageDrugPricesforTop-SellingDrugsin2015
Nondis-       Estimated
counted       Discounted
Adalimumab(Humira),40mgbiweekly         3430.82       2504.50       1164.32        981.79       1749.26
Fluticasone/salmeterol(Advair),250μg,     309.60       154.80          74.12         34.52        37.71
50μgdaily
Rosuvastatin(Crestor),10mgdaily           216.00         86.40         32.10         19.80        40.50
Trastuzumab(Herceptin),                 5593.47       4754.45                     2527.97       3185.87
450mgevery3wk
Eu   Thomas    Leitz
portador do  CPF/CNPJ       92584560410     / 11169063001164             e RG     36.587.854-6
na qualidade  de  beneficiário do seguro  residencial :
Número   da apólice:     28591
Data  do sinistro:       08          /     08            /  2018
Número  da Agência:                     Nome   da Agência:
Conta Corrente nº:      37794-0                               Dígito: 285
Nome:  Mauricio   Machado
Telefone: +55 98  3268-3357                        E-mail: mmachado@gpsbr.com
Plano  de Saúde: Plano  Padrão   Bronze  EPO   RealValue
MÊS  (ES) SOLICITADO    (S):
janeiro
Junho
novembro
Nome:  Mauricio   Machado
Matrícula SIAPE: 6547814                           Lotação:
Telefone: +55 98  3268-3357                        E-mail: mmachado@gpsbr.com
Plano  de Saúde: Plano  Padrão   Bronze  EPO   RealValue
janeiro
novembro
SERVIÇO       DE   OFTALMOLOGIA              – EMERGÊNCIAS            NO    TRAUMA        OCULAR
Claudio
Olho:    (   ) Direito  (    ) Esquerdo     (   ) Ambos     os  olhos    Tipo    de  Anestesia:      (   ) Local   (   ) Geral
(   ) Perfuração      ocular.
(   ) Perda    de  tecidos    oculares.
(   ) Presença      de  corpo   estranho     intraocular.
Nome  do (a) Candidato (a)
Data de nascimento 07 / 07 / 1993 Naturalidade
RG         40.464.525-2              órgão  expedidor Ainda não definido data exp 11/23/2020
CPF         02472176465
Título de eleitor:   Claudio Haddad                  Zona 5             Seção C
E-mail          chaddad@kpx.com.br
Ocupação  atual/ cargo Gerente
Instituição / órgão University of São Paulo
Instituição: University of São Paulo
computer,  web-based  and pharmacy-
Sealed envelopes                             !
Drug  containers of identical appearance     !
Other (specify)                              !
Not clear (free text)                        !
Número do Sinistro ou ASL             CPF da Vítima                          Nome completo da vítima
2971                                   03173940458                           Eduardo      Kugelmas
Alessandro   Vieira                                                               083844904-22                       engenheiro
Rod. ES-010,  1494  - Santa Luzia                                                               -                     -
-                                               Serra                                           ES                    29165-740
Email                                                                                                                 Telefone (DDD)
BRADESCO     (237)      BANCO    DO  BRASIL  (001)       ITAÚ  (341)                 BANCO Nome                                                       NRO
CAIXA   ECONÔMICA     FEDERAL   (104)                                                 Banco     do  Brasil                                                  -
AGÊNCIA                               CONTA                                               AGÊNCIA                                   CONTA
NRO.                         D/V      NRO.                         D/V                    NRO.                         D/V          NRO.                         D/V
-                        17391-6                        -                          -                       -           400.326-8                     -
(Informar dígito se existir)             (Informar dígito se existir)                         (Informar dígito se existir)             (Informar dígito se existir)
Nova    Friburgo    , 04      de 09                       de 2019
Jurisdiction   Medicine  type                Description
New            All medicines, including      The New  Zealand  Pharmaceutical Management    Agency
and  determining medicine prices. These methods  include
Jurisdiction        Mark-up  structure  in national currency                             Dispensing
(currency)                                                                               fee
Type          Base price and threshold   Mark-up   level
Australia           Regressive    Approved   pharmacist                                  $ 7.15
(Australian                       price:                      • $ 3.94
dollar)                            • $ 0.00 to $ 180.00       • $ 3.94 + 3.5% 
• $ 180.00 to $ 2,089.71    amount   >$ 180
• >$ 2,089.71
(Danish kroner)                                                1.25  1.084) + DKr
prices                                                 faith-based
sectors)
(New  Zealand                      • <$ 150                   • 4%                       Information
dollar)                            • ≥$ 150                   • 5%                       unavailable
South Africa        Regressive    Exit price:                                            Maximum:
(South African      (with          • R 0.00 to R 107.15       • 46%                      • R 11.25
rand)               progressive    • R 107.15 to R 285.80     • 33%                      • R 24.00
dispensing     • R 285.80 to R 1000.33    • 15%                      • R 73.50
fee)           • R >1000.33               • 5%                       • R 172.00
1   ALL CHARGES
1   Meals                   1   Bar / Lounge         1    Fax / Copy
1   Valet Parking           1   Other (Specify)
NOME DO MÉDICO :                                                                               CRM:
NOME DO PACIENTE:
Renato   Guerra    Mendes
RUA    JAPÃO     38                                                                           (11) 3191-1000
BAIRRO:                        CIDADE:                         CEP:                             E-MAIL :
Rio  Largo                       57100-000                     rgm@energyworks.com.br
DATA:                 VALOR TOTAL DAS DESPESAS:           ASSINATURA  DO EMPREGADO:
Nº DO BANCO/NOME:                 NÚMERO/NOME    DA AGÊNCIA:          Nº CONTA  CORRENTE:      CPF N.º
Cirurgião ou Clínico
Anestesista
3º Auxiliar
Medicamentos
TOTAIS:  R$
OBSERVAÇÕES    COPASS   SAÚDE:
Citizenship Status 2     Citizen of United States   Social Security Number  3 253987134
Current Address     1360  E PKWY   DRAPER    UT  84020  USA
Date of Birth  03-05-1992                           Place  of Birth CA
Nome  completo: Andre   Jakurski                                                  Data de nascimento: 02  / 06   / 95
Médico solicitante: Ana Cristina Reif  de  Paula                                   Número do CRM: 65247
Nome   do paciente:
Assinatura do paciente:
Testemunha   1:
Assinatura da testemunha   :
Assinatura da testemunha:
1.   How  important   is the topic
()            ()            ()            ()             ()
(b)  to researchers?
()            ()            ()            Q)             ()
]             2             3             4              5
of no                                                 extremely
importance                                               important
2.  Are  the research  methods   appropriate?
Yes
_  No  (explain)
3.   Predict the outcome   of the study.
When   you  complete  these  three items, open  the  envelope  containing  the manuscript   and
review it by following the structured guide (which is mandatory  for this special review process).
REFEREE’S     RATING     SHEET
[CHECK     HERE    IF  ‘NOTE   TO   REFEREES’     WAS    PROVIDED       0]
1.  How   important  is the topic
(a) to practitioners?
importance                                               important
Modalidade:      (   ) Integrado                   Ano:   2018
A: Chemotherapy, Chemotherapy Administration, and Related Drugs
t
k
f-   $1,200
o              F: Professional and Other Services excl. Chemo and Rad Therapy                                      OON
t-   $1,000
u  t
n t C o $600
t e    $400
P a    $200
1
1        $0
2 0             A     B    C    D     E    F     A    B    C     D    E     F    A     B    C    D     E    F
Company/Purchaser    Name:  Rodney Due
City: Los Angeles                          Country/State:  CA            Zip/Postal Code:  90045
Home   Phone: (928)474-4202                  Work Phone:  (310) 242-5240
Central allocation (including telephone,     !
controlled randomization)
Drug  containers of identical appearance     !
Not clear (free text)                        !
CONTACT      INFORMATION:                                           PHONE     &  EMAIL
Dean    Scharmen      Manager                                       (231)853-2261
City. State. Zip                                                    Fax
New   York  NY   10023                                              n/a
Sentinel  High  School                                              dscharmen@irbcity.com
Sports Coached
PAYMENT      INFORMATION                                            CLINIC    LOCATION      &  DATE:
5    Credit Card Number  & Expiration                               Location
4640188001575035                                                    n/a
5    PO  # (Must have hard copy attached to form)                   Presenter
5    Check  # (Must be attached to form)
5  OTHER COACH                              5  OTHER
5    WALK   UP  COMPLETE    5CC,   5CHECK,    5PO
5    WALK   UP  SHIP  TO COMPLETE     5CC,   5CHECK,    5PO
DADOS   DO  CANDIDATO
Nome:                    Arthur Pesquisa
Cargo/função   pretendido:   Assistente Administrativo
Física                   Auditiva                 Visual
Mental                   Múltipla                 Outra:
1% increase  in
Price                                                   +11.10%
Variable  cost
Volume               +3.30%
Fixed cost       +2.30%
Please state the reason why  you require a static IP address:
Technical  Contact Name:   Valerie Clarke
Technical  Contact E-Mail  Address:  clarke.valerie@flsenate.gov
Technical  Contact Telephone   Number   (business hours): (954) 484-4000
the internet connection: A9:F1:08:6F:6D:63
Do  you require a specialized reverse DNS  entry for this static IP assignment: No
Please read and  initial the following:
I understand  and agree  that BPS maintains  a dynamic  border  firewall and that BPS
is under no obligation to modify or remove  an  IP address, port or net block from the
has been blocked.
Initial:
I understand  and agree  that BPS may  revoke  the static IP address assignment
without notice for any reason  including but not limited to – abuse complaints,
Initial:
any reason  with at minimum   5 working  days notice.
Static DHCP   Entry:  -
PPPoE:
Password:   jtig8177
Default  Gateway   IP:
DNS   Servers:
Telefone(s): +55  98 99608-4062                                                                ,
E-mail: ajakurski@jgp.com.br                                                                   ,
Curso:     História                                                                           ,    Turno:
(Obrigatório para quem  optar pelas ações afirmativas de pessoas com  necessidades especiais)
Curso:     História                                                                           ,    Turno:
10 hours               , Campus:  Juiz de Fora                                          ,
UNIVERSIDADE   FEDERAL  DO  CARIRI
INSTITUTO DE FORMAÇÃO    DE  EDUCADORES
Coordenação  do Curso de Licenciatura Interdisciplinar
Registro de orientação de TCC
Alteração de orientador(a) de TCC
Exclusão de atividade TCC
Projeto de Pesquisa
TCC  I
TCC  III
DADOS  DO DISCENTE
Andre Debars
debars@hotmail.com                                           +5598981517978
Curso
DLD
Geraldo Coen
Coordenador(a)  de TCC do curso
(1) Foreign currency  reserves  (in convertible foreign currencies)                   92,525
(a) Securities (Note  2)                                                              81,425
of which:  issuer headquartered   in Hong  Kong  but located abroad                         0
(b) total currency and deposits  with:                                                11,100
(i) other national central banks, BIS and  IMF  (Note  3)                               3,608
of which:  located abroad                                                                   0
(iii) banks headquartered  outside  Hong  Kong   (Note  4)                              4,766
(2) IMF reserve  position                                                                   0
(3) SDRs
—volume    in fine troy ounces   (66,916  ounces  at USD  276)
(5) other reserve assets  (specify)                                                     1,396
—financial  derivatives  (Note  5)                                                        -81
—other   (Note  6)                                                                      1,477
B. Other  foreign currency assets  (specify)   (Note  7)                                   19
—securities  not included  in official reserve assets
—deposits   not included  in official reserve assets                                       16
—loans   not included in official reserve assets
—gold   not included in official reserve assets
—other                                                                                      3
To sign up for direct deposit of your federal benefit payments such as Social Security, SSI or VA Compensation
• Go  to the U.S. Department  of the Treasury website: www.godirect.org,    or
• Enroll by phone by calling the U. S. Department  of the Treasury toll free at: 1-800-333-1795
• 12-digit federal benefit check number                   • TD  Bank account  number:
• Amount   of most recent federal benefit check           • Type of account  (checking or savings):
Employee  ID:
o  Total net check amount
o  The set amount  of $                                  of my  net check each period.
Address:                                        32 Chestnut  St.
P.O. Box 1377
TD Bank  account number:
Type of account:                                o  Checking    o  Savings
Signature of officer:                                                            Date: 01/10/2018
01/10/2018
Signature of adviser:                                                            Date:
Signature of parent:                                                             Date: 01/10/2018
CURSO:         Engenharia     de   software   101
Banco:   Banco    do  Brasil   Agência:    Centenário          Conta:      26224-2           (  ) Conta Corrente
(  ) Conta Poupança
Solicito    o    Auxílio    Emergencial     conforme      Edital   nº     05   /2019,    no     valor    de    R$
1500/-                           DECLARO      que estou ciente das condições estabelecidas no referido Edital
do Programa  de Assistência Estudantil do IFTO e preencho os requisitos solicitados, sujeito a comprovação.
Formoso  do Araguaia  - TO, 11    de 16                de 2019.
Recebi, nesta data, o formulário de inscrição ao Auxílio Emergencial  do estudante acima identificado, conforme
a. NAME    (Typed  or printed) (Last, First, Middle Initial)                     b.  UNIQUE    IDENTIFICATION     (e.g., EDIPI, UID)
Area  Code)
(1) TYPE   (DoD  ID, Passport,  etc.)    (2) NUMBER                                    (1) TYPE   (DoD  ID, Passport, etc.)     (2) NUMBER
Insured  Subscriber’s  Printed  Name     Paul   Stanek                                   Mobile   Number    (517)629-2900
Billing Address    7323    Washita     Way
Email  address  pstanek@dunedinfl.net                                       Contact  Number(s)    (231)861-4341
U.S. Passport                       Immigrant    Visa                   U.S.  Military ID
If your phone has been lost or stolen, you must report your phone as lost or stolen to your wireless carrier before submitting this
affidavit. You must request the phone  to be permanently disabled on your carrier’s network to prevent further usage.
Loss/Incident/Failure Date 08/04/2018
Check One:  My phone  was     Lost    Stolen   Damaged      Just Stopped Working
Description of loss, incident or failure -
http://jama.com/subscribe                                   http://jamaarchives.com/alerts
http://pubs.ama-assn.org/misc/permissions.dtl
CELDT  Results from 2011-2012 school year
Reading                               4 = Early Advanced
Writing                               5 = Advanced
Name
Telephone    (    )
Address
City/State/ZIP
Reason  for Payment
Signature                                                        Date
Card  Number:
Reason  for Payment
Card  Number:
PRONTO SOCORRO:                                                                                            Nº CARTÃO SUS:
04
NOME:
Marcio    Trigueiro
DATADE NASCIMENTO:    IDADE: ENDEREÇO:
22/09/1992           18         R.  Pasteur,    463  - Batel,   Curitiba,   PR,   80250-104,      Brazil
Dados  da Pessoa  Segura
Nome:  Andre   Jakurski                                                             N.º do Cartão: «I 376435374602005
N.º de Tel. Contacto: '+55  98 99608-4062                                           E-mail: ajakurski@jgp.com.br
Data  da Ocorrência:  09  / 09  / 2010                            Local:
R. Antônio de Albuquerque, 330 - 12nd floor - Savassi
Modalidade:  Lesões    relacionadas    a esportes
Tipo de Prática Desportiva:
Profissional □               Participação em  Competições  Organizadas   □                     Lazer □
3.2 ACIDENTE   ESCOLAR
Nome   da Companhia   de Seguros: Parte   Prática                                  Nº  Apólice: XEF900668620
Houve  participação do  acidente ao Seguro escolar?                Sim □                             Não  □
3.3 ACIDENTE   TRABALHO
Sim  □                             Não  □
Circunstâncias  em que  ocorreu
3.4 ACIDENTE   VIAÇÃO
Motivo  da deslocação:
3.5 OUTRO   ACIDENTE
Descrição  pormenorizada   do acidente e em caso de  deslocação o motivo  da mesma,  nomeadamente    local de onde vinha  e local
3.6 DOCUMENTAÇÃO      DE ENVIO   OBRIGATÓRIO    (CASO  SE APLIQUE):
2.  Nota de alta em caso de internamentos médicos ou cirúrgicos relacionados com o acidente;
a. Incident cases                                                   b. Prevalent  cases
CAMV:       Geraldo   Coen                                   M. Vet.: N/D
Email CAMV:      gcoen@pbrasil.com.br                         Telef.: +5598981517978
Proprietário:     Thomas   Leitz
Student Name:  William  Kirby             Student ID: K-65212                   Grade:  8th     Home
Composite  (Overall) Score: 7.5        Literacy Score: 8
Please  mark   all that apply   & return   the completed     form  to your   child’s school.
I will schedule a parent-teacher conference  to discuss the options  for my child.
Note: If this form is not returned within one (1) week, the district will assume agreement with the language
services decision and begin immediate  implementation   of educational programming.
Slovic, Paul and Fischhoff, Baruch (1977), “On the psychology  of experimental surprises,” Journal of
Experimental   Psychology:   Human    Perception  and  Performance,   3, 544-551.
Smigel, Erwin  O., and Ross, H. Laurence  (1970), “Factors in the editorial decision,” American  Sociologist, 5,
19-21.
Spiegel-Rosing,  Ina (1977), “Science studies: Bibliometric and content analysis,” Social Studies of Science,  7,
97-113.
Sterling, T. D. (1959), “Publication decisions and their possible effects on inferences drawn from tests of
significance –or vice versa,” Journal of the American  Statistical Association, 54, 30-34.
Cidade:    São   Sebastião                             UF:  RJ                  Fone:   (   ) Nenhum
Situação    acadêmica      na  IES  de  Origem:     (   ) Cursando     (   ) Trancado
CPT  CODE                                           DESCRIPTION
77261-77263                  THERAPEUTIC   RADIOLOGY: TREATMENT  PLANNING
77280-77299                  RADIATION  THERAPY SIMULATION
77300-77370                  RADIATION  PHYSICS SERVICES
DEVICES, AND  SPECIAL SERVICES
77418                        IMRT DELIVERY
77421                        STEREOSCOPIC   IMAGING GUIDANCE
77520-77525                  PROTON  THERAPY
77750-77799                  BRACHYTHERAPY
Nome:                                                                          Turma:   (1)  (2)  (3)  (4)
O  que  você  deseja   com  este  formulário?
(  )Sugestão    (  ) Elogio (  ) Reclamação     Formal
ocorrido:
C  ITY AND   C  OUNTY    OF  S AN   F RANCISCO                         O  FFICE  OF   THE  C ITY A  TTORNEY
D ENNIS J. H ERRERA                                  Direct Dial: (415) 554-4748
Email:
City Attorney                                                     brittany.feitelberg@sfcityatty.or
g
2.  HVLN   School  Site Facilitator:​ primary  contact   to support  HVLN   initiatives with your  school.
☐    New  Membership    for School Year 2019-2020   = $2,000
☐    Returning  Membership    for School Year 2019-2020  = $750
1.   Early Registration for E-School Courses
Principal’s Name   (Please Print)                    Signature                                 Date
Payment  Method​:  Checks only.      Step 1:​ Email completed membership  form/invoice to:
Department  of Education                     copy of the membership  form/invoice​ to Vendor Payment.
(Vendor #120523,  suffix 03)
Step 3:​ Vendor Payment  will mail the completed membership
ATP Type: ​Invoice with Check                form/invoice with payment  to​:
475 22nd  Avenue, Room  205
Honolulu, HI 96816
Or mail completed membership  form and payment  to
SEXO:                                       IDADE:              TELEFONE / FAX:
CEP:                         CIDADE:
SUGESTÕES                              ELOGIO                            RECLAMAÇÃO
David R. Cheriton School of Computer Science, University of Waterloo
Waterloo, ON, Canada
keshav@uwaterloo.ca
First                         Middle                                  Last
First                         Middle                        Maiden              Last
Religion: christian                                         Baptized?   Yes   No      First Eucharist?  Yes   No      Confirmed?      Yes  No
Are you a registered member   of St. Jude?  Yes  No  If no, which parish? Church    Christ
Marital Status:      Married                     Single                      Divorced                    Widowed
If married, were you married by a Catholic Priest?          Yes      No
Church  where you  were married:  Church     Christ
Signature:
Date:                    03-03-2018
Print Name:              Yoichi Takeda
Nome:
Pericles        Silva     Pereira
Nº  do  edital:                                    Número      de  Matrícula:               Curso    de  Graduação:
9032214                                             69356                                   Ciência        da    Computação
Data   de  Nascimento:                   Telefone:                                          Identidade     (RG):                            CPF:
15/12/1990                               +55     98   98513-3276                            474281462                                       089831264-77
E-mail   institucional:                                                                  Identidade E-mail alternativo: no :
BANCO      INTER     - (Rio  de   Janeiro)        R1                           Não      definido                                  74414-0
Dados     do  projeto
Nome     do  Projeto:
Otavio       Pontes
Departamento:
Ciência        da    Computação
Área   do  conhecimento                     (   ) Ciências    Agrárias                       (  ) Ciências    Exatas    e  da  Terra             (  ) Ciências     da  Saúde
extensão):                                  (   ) Engenharia/Tecnologia                      (  ) Linguística,    Letras   e  Artes
SOLICITAÇÃO       DE  DISPENSA/DESOBRIGATORIEDADE                DE  NFC-e
ENDEREÇO  (RUA, LOGRADOURO,   ETC.)                 NÚMERO       BAIRRO
CIDADE                                              CEP               TELEFONES
(cid:1) Exerço, preponderantemente, a(s) atividade(s) de:
a venda  de mercadoria  a pessoa física;
(cid:1) Cumpro os requisitos previstos nos incisos I e II do art. 272 (Decreto 44.650/2017)
Wages,  Salary                    $             /month           Housing                            $              /month
(rent, mortgage, etc.)
Other Income                      $             /month
employed/independent     contracting,
Checking  and/or Savings          $                                water, etc.)
Property                          $                              Transportation                     $              /month
(real estate, automobile(s),
spouse, other family members,   etc.)                          Signature of Alien                  Date
For each outcome:
How  many   subjects were lost
to outcome  follow up?
!!     !!    !!
enumerated  with reasons for loss?
outcomes?
Were  outcome  missing  data imputed or  !! Yes !! No !! Unclear
losses to follow up?
!!     !!    !!
Are reports  of the study free of suggestion     !!      !!     !!
of selective outcome   reporting?
,%"(-
10. Exames   complementares   para atletas nascidos em 1984  ou antes:
(i)  Raio-X de Tórax, (ii) Eletrocardiograma e (iii) Exame de Urina (EAS)
Nome   completo                                                           CPF
-                Thomas     Leitz                                         -    92584560410
Nome   de luta / Apelido                                                  Cor do Cabelo      Cor dos Olhos
Cidade:                        Estado:            País:                                 CEP:
Telefone:                                     E-mail:
-         011   55  61  99236-9548            -       thomas@leitz.ca
Masculino  / Feminino   Data de Nascimento:  Nacionalidade:              Altura:                   Peso:
05/05/1994 / /                BRASILEIRO         -      5  ft 10 inches    -  71  kg
Galo: Até 61,2 kg                                                 Mosca: Até 56,7 kg
Pena: Até 65,7 kg                                                 Galo: Até 61,2 kg
Leve: Até 70,3 kg                                                 Pena: Até 65,7 kg
Super Leve: Até 74,8
Meio-Médio:  Até 77,1 kg
Super Meio-Médio:  Até 79,4
Super Médio:  Até 88,4 kg
Meio Pesado:  Até 92,9 kg
Data do Exame Físico                                                  Assinatura e Carimbo do Médico
Nota: A Comissão permite que os atletas mudem de categoria de peso para cima, a critério do próprio atleta. No entanto, um atleta não
pode descer de categoria de peso sem aprovação prévia da Comissão.
1. Você já foi desqualificado em algum  combate  ou sofreu sanção  disciplinar por qualquer entidade de administração  de
desporto ou  comissão  atlética, seja por qualquer motivo?
3. Você já foi hospitalizado por problemas de corte de peso ou desidratação?   SIM    NÃO
5. Histórico no MMA  Profissional   Vitórias        Derrotas         Empates           NC
02/03/2019
Assinatura do Requerente                                        Data
Date of Birth                                        Health Plan ID
Fitness Facility Information
City                                                             County
State                                                            ZIP+4                      -
Type  of Arrangement
     Fitness Facility Agreement
Membership
     Individual membership                 Family membership    - If family membership,  list names below
     Month-to-Month                         Start Date                        End  Date
     Annual  Membership                     Start Date                        End  Date
Fitness Facility Attestation:
I,                                                                (fitness facility representative name), confirm
Fitness facility representative signature
Date
A(O)     Senhor(a)         Pró-Reitor(a)         de   Gestão       de    Pessoas
beneficiários (titular e dependentes) e os valores pagos para cada beneficiário;
3) CPF e RG  ou Certidão de nascimento do (as) filho(as), enteados(as) ou do menor sob guarda ou tutela concedidas por decisão judicial, enquanto
4) Para os filhos e enteados, entre 21 e 24 anos, na condição de estudantes, deverão ser apresentados comprovantes de curso regular reconhecido pelo
5) Cópia de certidão de casamento ou documentos comprobatórios para reconhecimento de união estável, inclusive se relação homoafetiva (três indícios de
união estável), RG e CPF do cônjuge/companheiro.
Obs.: Todas as cópias podem ser autenticadas na Central de Relacionamento mediante a apresentação do documento original.
INICIAL            ATUALIZAÇÃO/                             INCLUSÃO                       EXCLUSÃO                    TITULAR
CARGO                                                                                                TELEFONE/CELULAR
COD.    DEPENDENTE:            1  – Cônjuge     ou  companheiro(a)          2 –  Filho(a)      3  – Enteado(a)        4  – Guarda     Judicial
/      /                                                   Sim     Não
O recebimento da assistência à saúde suplementar (per capita), de acordo com a Portaria Nº 1, de 09 de março de 2017 SRH/ MPOG está condicionado à:
DATA
ASSINATURA   DO  REQUERENTE
Processo  Indeferido
Total de dependentes  definidos na Lei:                  Valor a ser reembolsado:
Data:         /     /                Assinatura
Nome   Arthur      Pesquisa
Estipulante/Subestipulante   Estipulante
N° de Certifi cado Individual ELC-1581417157-8573-2
Nome                                                 %participação   Grau de parentesco
Claudio     Haddad                                 30             pais
unless the purchaser gives him a fully                     FORM         ST-3
completed   New   Jersey  exemption
certificate.                                 RESALE             CERTIFICATE
(Name of Seller)                                             Manager203-90-4134
732  CENTER      DR                                           SAN   MARCOS                     CA                    92069
Address                                      City                         State                    Zip
The  undersigned   certifies that:
(4)  The  merchandise     described  in (3) above  is being purchased:   (check  one  or more  of the blocks  which  apply)
(a)  ¨   For  resale in its present form.
(b)  ¨   For  resale as converted   into or as a component    part of a product produced   by  the undersigned.
(c)  ¨   For  use  in the performance   of a taxable  service  on personal   property, where   the property  which  is the
subject  of this Certificate becomes    part  of the  property  being  serviced  or  is later transferred to  the
purchaser   of the service in conjunction  with the performance    of the service.
(5)  The  services  described  in (3) above  are being  purchased:   (check  the  block which  applies)
the undersigned purchaser, have read and complied with the instructions and rules promulgated pursuant to the New Jersey Sales and Use
Wood   furring, rigid insulation  and  ‘4 in.                16  in.              24  in.               16 in.      |        24  in.
(12 mm)   gymaum   board                        (400 mim}  o.c.      (600  mm)  oc.       (400  mam}  .oc       (00min)    cue.
“un. (12 iim)  extruded  palystyrana                                Be                   aa                   54                    BA
2. in (18 mm)  pebyisecyanuratio:                                   45                   50                   65                    6a
18 in. 438 rm)  eabrkied  polyshrnne                                a                    a5                   a2                    ed
16in, (38  um}  pahpsocyanurnts                                     es)                  B2                  12                   122
and    in,
Matal  turing.  rigid insulation       “4
(13 mm)   gypoum   beard
Tin, (25 mn)  eatnkted  polystyrene                                 a4                   42                   65                    a8
Vin, (25 mem) polysocyanurate                                       a5                   Sa                   BG                    eG
Thin. (38. im)  axtnusiod potystyenne                               46                   Ba                   a4                    a4
TCI.  (38  ein) polyieocyarmnurabe                                  a                    Ba                  aFan|                124
Approach            Description                  Method    of price determination
Other  measures     Efficient dispensing         1.   Determine  the  most cost-efficient combination   of vial sizes for injectable
to ensure                                             medicines  to minimize  wastage
efficiencies
Enhanced   competition       1.   Determine  pricing, prescribing and  dispensing  rules for generic and biosimilar
products
Prior authorization          1.   Selection of medicines  for which authorization  is required prior to dispensing
Regular  review of benefit   1.   Selection of medicines  for review according  to certain criteria (e.g. therapeutic
list                              value)
2.   Retain, amend   or delist medicines according  to review findings
Tax reduction  or            1.   Assess the appropriateness   of the level of tariffs and taxes related to the supply of
exemption                         medicines
2.   Apply tax reduction  or exemption   and ensure  savings  are transferred to
consumers
Pooled  procurement          1.   Seek alignment   in the goals for arranging pooled  procurement
2.   Combine   financial and non-financial resources  across  various purchasing
authorities to create a single entity for purchasing health products
3.   Seek to lower  prices of medicines  and stability of supply through economies    of
scale and stronger  negotiating  power
4.   Monitor  the progress  of the arrangement   against the goals  and make
modification accordingly
Nutrient               Biologic       Val./reproduc     Coef      Details
tissue
Enterodiol             Serum          Validity          0.13 to   Urinary  enterodiol and enterolactone and serum enterolactone were
Enterolactone          Urine                            0.29      significantly correlated with dietary fiber intake (r = 0.13-0.29) Cancer
Epidemiol  Biomarkers  Prev. 2004  May;13(5):698-708
Prescribing using
Substitution                International         Authorizing personnel:
doctor or pharmacist
Nonproprietary  Names
Jurisdiction   Generic       Biosimilar      Generic      Biosimilar  Generic        Biosimilar
Australia                                                         Pharmacista   Pharmacista
Austria                                                           Doctor        Doctor
Belgium           (M)                                             Either        Doctor
Denmark                                                            Either        Doctor
Lebanon                                                           Pharmacista   Doctor
Finland           (M)                                             Pharmacista   Doctor
Franceb,c                                    (M)                  Pharmacista   Pharmacista
Germanye                                                          Either        Either
Greece            (M)                        (M)                  Either        Doctor
Japand                                                            Pharmacista   Doctor
Ireland                                                           Pharmacist    Doctor
Italy             (M)                        (M)                  Either        Doctor
Netherlands       (M)                        (M)                  Either        Doctor
Poland                                                            Either        Doctor
Portugal          (M)                        (M)                  Pharmacist    Doctor
Spain             (M)                        (M)                  Either        Doctor
Sweden            (M)                                             Either        Doctor
United Kingdom                                                    Either        Doctor
Název    organizace:                                                                                      Kurz  EUR/CZK      (záloha):
Číslo   projektu:                                                                        Kurz  EUR/CZK      (průběžná    platba):
Počet       Sazba  za       Rozpočet  dle    Vyčerpáno  celkem     Odchylka       Odchylka
Náklady                                              Jednotka    jednotek    jednotku (v €)       smlouvy               v €             (v €)           (v %)               Vysvětlete odchylky od schváleného   rozpočtu:
1. Lidské    zdroje
1.1 Platy (celkový  plat včetně  odvodů,   místní zaměstnanci)
1.1.1 Realizátoři, koordinátoři, vedoucí projektu, atd.                                      měsíc              0               0                   0                  0              0     #DIV/0!
1.1.1.1. Koordinátor projektu                                                                měsíc              0               0                   0                  0              0     #DIV/0!
1.1.2 Administrativní/podpůrní zaměstnanci                                                   měsíc              0               0                   0                  0              0     #DIV/0!
1.2 Platy (celkový  plat, zahraniční  pracovníci)
1.2.1 (…)                                                                                    měsíc              0               0                   0                  0              0     #DIV/0!
1.2.2 (…)                                                                                    měsíc              0               0                   0                  0              0     #DIV/0!
1.2.2 (…)                                                                                    měsíc              0               0                   0                  0              0     #DIV/0!
1.3 Diety
1.3.1 Do zahraničí (pro zaměstnance pracující na projektu)                                    den               0               0                   0                  0              0     #DIV/0!
1.3.2 Místní (pro zaměstnance pracující na projektu)                                          den               0               0                   0                  0              0     #DIV/0!
1.3.3 Seminář/účastníci konference                                                            den                                                   0                  0              0     #DIV/0!
Mezisoučet     lidských   zdrojů                                                                                                                     0           0.00   €         0.00  €    #DIV/0!
2. Cestovné
2.1 Mezinárodní cesty                                                                            let              0               0                   0                  0              0     #DIV/0!
2.2 Místní přeprava (nad 200 km)                                                               měsíc              0               0                   0                  0              0     #DIV/0!
Mezisoučet     cestovného                                                                                                                            0           0.00   €         0.00  €    #DIV/0!
3. Technika      a zboží***
3.1 Nákup nebo pronájem vozidla                                                                vozidlo            0               0                   0                  0              0     #DIV/0!
3.2 Nábytek, počítačové vybavení                                                                 ks               0               0                   0                  0              0     #DIV/0!
3.3 Náhradní díly/zařízení pro stroje, nářadí                                                                                                         0                  0              0     #DIV/0!
3.4 Jiné                                                                                                                                              0                  0              0     #DIV/0!
Mezisoučet     techniky   a zboží                                                                                                                    0           0.00   €         0.00  €    #DIV/0!
4.Místní    kancelář/náklady        projektu
4.1 Náklady vozidla                                                                            měsíc              0               0                   0                  0              0     #DIV/0!
4.2 Pronájem kanceláře                                                                         měsíc              0               0                   0                  0              0     #DIV/0!
4.3 Spotřební materiál - kancelářské zboží                                                     měsíc              0               0                   0                  0              0     #DIV/0!
4.4 Jiné služby (tel/fax, elektřina/topení, údržba)                                            měsíc              0               0                   0                  0              0     #DIV/0!
Mezisoučet     místní
kancelář/náklady      projektu                                                                                                                       0           0.00   €         0.00  €    #DIV/0!
Exposure                Measured      Valid?    Reason  (Willett)                                Reason  (Margetts  / Nelson)
in
Saturated fatty acids    Adipose      Yes     Yes, long term sat fatty acid intake may be        No info
(Palmitic acid, stearic  tissue       No      reflected in adipose tissue levels (p 224)
acids)                   Plasma               No, levels of palmitic and stearic acids in
plasma  do not provide a simple index of intake
(p 224).
Trans-fatty acids        Adipose      Yes     Yes (p 225)                                        No info
tissue
Protein                  Any          No      No  (p 226)                                        No
info
Nitrogen                 Urine        Yes     Yes, but several 24-h samples are needed  to       Yes (p 219) One  assumes  that subjects are in
provide a stable estimate of nitrogen intake (p    nitrogen
227) Nitrogen  excretion increases with body       Balance
size and exercise and decreased caloric intake
Stage at   # of patients 0-6 months      0-12 months      0-18 months      0-24 months
diagnosis  at diagnosis  postdiagnosis   postdiagnosis    postdiagnosis    postdiagnosis
0          2300          $48,477         $60,637          $67,450          $71,909
I/II       4425          $61,621         $82,121          $91,109          $97,066
III        1134          $84,481         $129,387         $147,470         $159,442
IV         501           $89,463         $134,682         $162,086         $182,655
All        8360          $62,774         $85,772          $96,499          $103,735
Stage at    Total   Non-       Hispanic   Black   Chinese    Japanese   South    Other   Other
diagnosis           Hispanic   White                                    Asian    Asian
White
I           48.0    50.8       40.1       37.0    50.1       56.1       40.4     45.2    43.6
II          34.6    33.2       38.7       38.6    35.7       32.4       38.7     38.1    37.2
III         12.4    11.4       15.9       16.6    10.7       8.5        15.3     12.4    13.5
IV          5.0     4.6        5.3        7.8     3.5        3.0        5.6      4.3     5.7
Highest Average  Accuracy
Overall
Feature    Accuracy    Accuracy    Accuracy    Accurac    Standard
Set         (Weak)     (Medium)     (Strong)              Error
y
1          0.83        0.98        1           0.96       0.0063
1+3        0.83        0.98        1           0.96       0.0063
1+4        0.83        0.98        1           0.96       0.0062
1+5        0.83        0.98        1           0.96       0.0062
1+6        0.83        0.98        0.89        0.95       0.0062
2          0.83        0.98        1           0.96       0.0061
2+3        0.83        0.98        1           0.96       0.0061
2+4        0.83        0.98        1           0.96       0.0061
2+5        0.83        0.98        1           0.96       0.0062
2+6        0.92        0.98        0.89        0.96       0.0062
2+6+3      0.92        0.98        0.89        0.96       0.0062
2+6+4      0.83        0.98        0.89        0.95       0.0065
2+6+5      0.83        0.98        0.89        0.95       0.0065
Exposure                Measured       Valid?     Reason  (Willett)                                 Reason   (Margetts  / Nelson)
in
Zinc                      Any          No       No (p 212)  May  be marker  of short-term intake    No  biochemical  marker  is a good indicator of
Metallothionein  levels                No       (p 213)                                             zinc intake (p 192/193). This  is, in general
terms, also true for other trace metal nutrients
such  as copper, manganese,  chromium,   etc
Lipids: total fats        Any          No       No (p 213)                                          No,  there are no markers of total fat intake (p
215)
Cholesterol, LDL          Serum        No       No, but may  be useful to predict dietary changes   No,  relationship dietary cholesterol and
Lipoprotein  levels                             but not for dietary intake (p 215)                  lipoprotein levels of cholesterol are complex
and  appears to vary across range of intake
(p218)
Linoleic acid             Plasma       No       Plasma  linoleic acid can discriminate between      No  consistent relation between  dietary linoleic
groups with relatively large differences in intake  acid intake and plasma  linoleic acid (p 220).
but performs less well on an individual basis (p    Across  the range of fatty acids in the diet, fatty
Adipose      Yes      220)                                                acids levels in blood and other tissue (adipose
tissue                Yes (p 220)                                         tissue) reflect the dietary levels. NB levels are
not comparable   across tissues
Marine  omega-3   fatty   Serum        Yes      Yes (p 222/223),  although dose-response
acids (EPA,  DHA)         Plasma                relation
Adipose               remains to be determined
tissue
Monounsat   fatty acids   Plasma       No       No, plasma  levels are poor predictors of oleic
(oleic acid)              Adipose      No       acid intake, but adipose tissue may weakly
tissue                reflect oleic acid intake (p. 224). Validity is too
low
Polyunsat  fatty acids    Adipose      Yes      Yes (p 220)                                         No  info
tissue
Nutrient                Biologic       Val./reproduc      Coef      Details
tissue
Iron (ferritin)         Serum          Validity           0.16      Borderline 0.16 correlation with heme  intake but only r-0.15 with total iron
intake (Willett p 208). Included as marker of iron storage
Copper  (Superoxide     Erythrocyte    -                  -         S.O.D  levels reflect both depletion and repletion of Cu (Willett p 212)
dismutase)
Selenium                Serum          Validity           0.63      Correlation between  selenium  intake and serum selenium  in South Dakotans
(n=44)(Willett, p 186)
Reproducibility    0.76      Average  correlation between repeated  measurements   at four 3-month intervals
in 78 adults (Willett, p 188)
Toenails       Validity           0.59      Correlation between  selenium  intake and toenail selenium level in South
Dakotans  (n=44) (Willett, p 186)`
Reproducibility    0.48      Correlation for selenium levels in toenails collected 6 years apart from 127 US
women   (Willett, p 206)
Whole          Validity           0.62      Correlation between  selenium  intake and whole blood  selenium  in South
blood                                       Dakotans  (n=44) (Willett, p 186)
Reproducibility    0.95      Average  correlation between repeated  measurements   at four 3-month intervals
in 78 adults (Willett, p 188)
Linoleic acid           Adipose        Validity           0.57      Correlation between  dietary linoleic acid intakes determined from 7-day
tissue                                      weighted  diet records and the relative proportion of linoleic acid in adipose
tissue in Scottish men (n=164). Also correlation between  linoleic acid measured
in adipose tissue and calculated from FFQ  in 118 Boston-area  men  (Willett, p
220)
Eicosapentaenoic        Adipose        Validity           0.40      Correlation with intake estimated from  three 7-day weighted food  records
(n-3)                   tissue                                      (Willett, p 223).
Reproducibility    0.68      Correlation over 8 months  in 27 men  and women   aged 20-29  (Willett, p 223).
Plasma         Validity           0.23      Correlation of cholesterol ester fraction and intake in 3,570 adults (Willett, p
223)
Reproducibility    0.38      Correlation of two measurements   taken 6 years apart in study of 759 Finnish
youths (Willett, p 219)
Size  of Room         Width   of Fireplace   Opening    in Inches
in Feet             in Short  Wall            in Long   Wall
10x14                     24                     24 10 32
12x16                  28  lo 36                 32 10 36
12%  20                32 to 36                  36 to 40
12%  24                32  to 36                 36 to 48
14%  28                32  lo 40                 40 to 48
16x  30                36 to  40                 48 to 60
20 x 36                40 to 48                  48 to 72
Nutrient               Biologic       Val./reproduc     Coef      Details
tissue
Vitamin  D: D25        Plasma         Validity          0.35      Correlation between  FFQ  estimate of vit D intake (including supplements) with
(OH)D                                                             plasma  D25 (OH)D   (n=139). Correlation excluding supplement  users: r=0.25
(Willett, p 199)
0.18      Cross-sectional correlation between dietary intake of nutrients and biochemical
markers in UK  pre-school child study in females (n=350). In males (n=365)
r=0.06 (Margetts, table 7.9b).
Serum          Validity          0.24      Correlation between  estimated vit D intake from food and supplements (based
on 24 h recall) and serum D25 (OH)D   (n=373  healthy women).  Food  only:
r=0.11 (Willett, p 199).
Vitamin  C             Plasma         Validity          0.43      Unadjusted  correlation between questionnaire-derived dietary ascorbic acid
intake and plasma ascorbic acid concentration in a heterogeneous population.
Diet only: r=38 (Table 9.1). Correlation is 0.31 for leukocyte ascorbic acid
concentration.(Willett, p 200)
Reproducibility   0.28      Repeated  measures in men  obtained 6 years apart (Willett, p 201)
Validity          0.43      Cross-sectional correlation between dietary intake of nutrients and biochemical
markers in UK  pre-school child study in males (n=369). In females (n=354)
r=0.39 (Margetts, table 7.9b).
Serum          Validity          0.55      Correlation between  food-frequency questionnaire estimate of vit C intake and
serum  vit C values (in smokers) in 196 men in Scotland (adjusted for total
energy intake, BMI  and serum  cholesterol level). Non-smokers: 0.58 (Willett, p
200/201)
Leukocyte      Validity          0.49      Correlation between  one week  of intake data and a single leukocyte ascorbate
measurement   for men. For women:  r=0.36. Nutrition survey of elderly in UK
(Margetts, p 211)
Vitamin  B6            Plasma         Validity          0.37      Correlation between  B6 and plasma  pyridoxal phosphate levels in 280 healthy
Urinary        Validity          -         men  =0.37 (Willett p203)
Folacin                Serum          Validity          0.56      Correlation of 0.56 in Framington Heart study 385 subjects (serum)
Erythrocyte                      0.51      Correlation in 19 elderly subjects (erythrocyte) (Willet p204)
Magnesium              Serum          Validity          0.27      Correlation between  intake with supplements 0.27 in 139 men  and 0.15 without
supplements  (Willett p211)
target word        senses Maj. Humphrey               SenseClusters              Our Approach
et al. 2006 exact cluster stopping gap cluster stopping CUI!ST
unigram   bigram    unigram   bigram   unigram bigram
adjustment           3   66.67   76.67     49.46     38.71     55.91    45.16     44.57   47.83
blood pressure       3   54.00   41.79     40.00     46.00     51.00    54.00     38.38  38.38
degree               2   96.92   97.73     53.85     55.38     53.85    55.38     70.31   48.44
evaluation           2   50.00   59.70     66.00     50.00     66.00    50.00     51.52   51.52
growth               2   63.00   70.15     66.00     52.00     66.00    63.00     63.64   63.64
immunosuppression    2   59.00   74.63     67.00     80.00     67.00    80.00     50.51  43.43
mosaic               2   53.61   67.69     72.22     58.57     61.86    50.52     37.50   22.92
nutrition radiation  2 2 50.56 62.24 35.48 78.79 40.45 69.39 47.19 56.12 44.94 69.39 41.57 56.12 25.00 57.73 37.50 60.82
repair               2   76.47   86.36     86.76     73.53     86.76    73.53     37.31   41.79
scale                2   100.0   60.47     100.0     100.0     100.0    100.0     51.56   96.88
sensitivity          2   96.08   82.86     41.18     41.18     52.94    54.90     48.00   18.00
white                2   54.44   55.00     80.00     53.33     80.00    53.33     49.44   49.44
average                  67.92   68.26     64.02     57.85     65.82    59.81     48.11   47.74
target word                      pseudo-   test  train Maj. Sense          Our Approach
word                      Clusters CUI   ST  CUI+STCUI!ST
actin-antigens                   a a     3319329872363.44    91.30 53.9544.81   54.17
angiotensin II-olgomycin         a o      5256  4729493.97   56.76 16.6220.68   17.73
dehydrogenase-diastolic          d d     2260620344158.57    95.85 45.7843.94   45.70
endogenous-extracellularmatrix   e e     1982017836479.92    71.21 74.3465.37   73.37
allogenic-arginine-ischemic      a a i   2291520622457.16    69.03 47.6824.60   33.77   32.07
X chromosome-peptide-plasmid     x p p   4610241490474.61    66.21 20.0431.60   42.89   42.98
diacetate-apamin-meatus-enterocyted a m e 1358  1221225.95   74.23 28.8724.08   26.07   22.68
Jessica English                            Shy-Quon   Ely II
Principal                                  Head  of School
317.226.4242                               317.226.4242
jenglish@igniteindy.org                    sely@igniteindy.org
Height   Lateral        Minimum    Internal Area of Chimney,   A,
H,        L,                        Square  Feet
Feet      ‘Feet     0.26       0.35      0.47       0.66       0.92
2         130       180        247       400        580
6        5         118       164        230       375        560
2         145       197        265       445        all
a        5         133       182        246       422        Bag
o        123       169        233       400        598
2         161       220        297       490        722
10        5         147       203        276       465        Fig
o        137       189        264       444        BES
5        125       175        246       424        534
2         178       249        335       560        B40
5         163       230        312       5a         825
15         o        151       214        294       504        Fra
5        138       198        278       494        738
20        128       184        26        459        706
2        200        273        374       625        960
5         183       262        348       594        930
20         o        170       236        330       562        BFS
5        156       27         |         536        835
20        144       202        292       510        B00
2        215        302        420       715         410
5         195       27g        39        5280        ogo
30         0        182       260        370       B44         o20
5        168       240        349       B15        aFS
20        155       223        327       585        932
30       MRY        182        26        544        BES
2        250        350        APS       B10         240
5        228        324        442       77          220
50        10       212        304        420       728         440
15        195       278        395       B95         oso
20        180       258        370       B60         o40
30       MRP        MRP        318       610        g7O
6         7          8         10         42
Single-¥¥all Vent Connector
Diameter, DO. Inches
Nutrient               Biologic       Val./reproduc     Coef      Details
tissue
Enterodiol             Serum          Validity          0.13 to   Urinary  enterodiol and enterolactone and serum enterolactone were
Enterolactone          Urine                            0.29      significantly correlated with dietary fiber intake (r = 0.13-0.29) Cancer
Epidemiol  Biomarkers  Prev. 2004  May;13(5):698-708
Prepatency                                      Survival
Day 3                          Day 5                         Day  10
No  treatment                              19 (19)                        19 (19)                         3 (19)
Metformin                                  17 (20)                        19 (20)                        16 (20)
Primaquine                                  3 (10)                         3 (10)                        10 (10)
Metformin/Primaquine                        1 (10)                         6 (10)                        10 (10)
Mefloquine                                  5 (5)                          5 (5)                          5 (5)
Metformin/Mefloquine                        4 (5)                          3 (5)                          5 (5)
Jurisdiction       Mark-up   structure in national currency                            Dispensing
(currency)                                                                             fee
Type           Base price and threshold  Mark-up  level
Turkey             Regressive     Wholesale price:
(Turkish lira)                    • TL 0 to TL 100.00        • 25%                     Nil
• TL 100.01 to TL 200.00   • 16%
• TL >200.00               • 12%
DRUGS           CONDITIONS          REFERENCES
Scopolamine         Depression           83, 91-94
“              Manias                102
“             Anxiety                93
Hydroxyzine          Anxiety               84-86
“               Panic               87-88
Promethazine         Anxiety                90
Orphenadrine        Depression            99-100
Tofenacin         Depression            99, 101
Author                                 Number   of publications                     Number   of coauthorships                       Cluster
Nosten, F.                                        35                                            148                                    2
White, N. J.                                      28                                            186                                    2
Imwong,   M.                                      25                                            131                                    2
Price, R. N.                                      25                                            88                                     7
Roper, C.                                         23                                            15                                     1
Plowe, C. V.                                      21                                            74                                     4
Pradines, B.                                      21                                            28                                     5
Dondorp,  A. M.                                   20                                            149                                    2
Rosenthal, P. J.                                  20                                            22                                     1
Udhayakumar,   V.                                 19                                            31                                     1
Alifrangis, M.                                    17                                             8                                     1
Kenangalem,   E.                                  17                                            55                                     7
Rogier, C.                                        17                                            27                                     5
Meshnick,  S. R.                                  16                                            35                                     1
M´ enard, D.                                      24                                            41                                     5
Sutherland, C. J.                                 16                                            22                                     1
Anstey, N. M.                                     15                                            51                                     7
Fairhurst, R. M.                                  15                                            81                                     6
Fidock, D. A.                                     15                                            14                                     3
Na-Bangchang,   K.                                15                                             3                                     3
Ringwald,  P.                                     15                                            70                                     6
Roepe,  P. D.                                     15                                             5                                     3
Wirth, D. F.                                      15                                             6                                     3
Exposure                Measured      Valid?    Reason  (Willett)                                Reason  (Margetts  / Nelson)
in
Saturated fatty acids    Adipose      Yes     Yes, long term sat fatty acid intake may be        No info
(Palmitic acid, stearic  tissue       No      reflected in adipose tissue levels (p 224)
acids)                   Plasma               No, levels of palmitic and stearic acids in
plasma  do not provide a simple index of intake
(p 224).
Trans-fatty acids        Adipose      Yes     Yes (p 225)                                        No info
tissue
Protein                  Any          No      No  (p 226)                                        No
info
Nitrogen                 Urine        Yes     Yes, but several 24-h samples are needed  to       Yes (p 219) One  assumes  that subjects are in
provide a stable estimate of nitrogen intake (p    nitrogen
227) Nitrogen  excretion increases with body       Balance
size and exercise and decreased caloric intake
Near-Term    Options                                                                         Next-Term    Options
Calls                             Puts                                                       Calls                             Puts
Strike                                                                                       Strike
Bid              Ask              Bid             Ask                                        Bid              Ask              Bid              Ask
800            1160.90          1164.40            0.00            0.10
900            1060.90          1064.50            0.00            0.10
1000            961.00           964.50            0.00            0.10
1050            911.00           914.50            0.00            0.10
1100            861.00           864.60            0.00            0.05
1125            836.00           839.60            0.00            0.05
1150            811.00           814.60            0.00            0.05
1175            786.10           789.60            0.00            0.05
1200            761.10           764.60            0.00            0.05
1220            741.10           744.60            0.00            0.10
1225            736.10           739.60            0.00            0.05                      1225            735.90           738.80            0.00             0.10
1240            721.10           724.60            0.00            0.10                      1250            710.80           713.80            0.00             0.10
1250            711.10           714.60            0.00            0.05                      1275            686.00           688.70            0.05             0.10
1260            701.10           704.60            0.00            0.10                      1300            660.90           663.80            0.00             0.10
1270            691.10           694.60            0.00            0.10                      1325            635.90           638.60            0.10             0.20
1275            686.10           689.60            0.00            0.10                      1350            610.90           613.60            0.10             0.20
1280            681.10           684.60            0.00            0.10                      1375            585.90           588.70            0.10             0.25
1290            671.10           674.70            0.00            0.10                      1400            561.00           563.70            0.15             0.25
1300            661.10           664.70            0.05            0.10                      1425            536.00           538.80            0.20             0.30
1305            656.10           659.70            0.00            0.10                      1450            511.10           513.80            0.25             0.35
1310            651.10           654.70            0.00            0.10                      1475            486.10           488.90            0.30             0.40
1315            646.10           649.70            0.00            0.10                      1500            461.20           464.00            0.35             0.45
1320            641.20           644.70            0.00            0.10                      1510            451.30           454.00            0.35             0.50
1325            636.20           639.70            0.05            0.10                      1520            441.30           444.00            0.40             0.50
1330            631.20           634.70            0.00            0.10                      1525            436.30           439.10            0.40             0.55
1335            626.20           629.70            0.00            0.15                      1530            431.30           434.10            0.45             0.55
1340            621.20           624.70            0.00            0.15                      1540            421.40           424.10            0.45             0.60
1345            616.20           619.70            0.00            0.15                      1550            411.40           414.20            0.50             0.60
1350            611.20           614.70            0.05            0.15                      1555            406.40           409.20            0.50             0.65
1355            606.20           609.70            0.05            0.35                      1560            401.40           404.20            0.55             0.65
1360            601.20           604.70            0.00            0.35                      1565            396.50           399.20            0.55             0.70
1365            596.20           599.70            0.00            0.35                      1570            391.20           394.00            0.60             0.70
1370            591.20           594.70            0.05            0.35                      1575            386.50           389.30            0.60             0.75
1375            586.20           589.70            0.10            0.15                      1580            381.50           384.30            0.60             0.75
1380            581.20           584.70            0.10            0.20                      1585            376.60           379.30            0.65             0.75
1385            576.20           579.70            0.10            0.35                      1590            371.30           374.10            0.65             0.80
1390            571.20           574.70            0.10            0.35                      1595            366.60           369.40            0.70             0.80
1395            566.20           569.70            0.10            0.15                      1600            361.60           364.40            0.70             0.85
1400            561.20           564.80            0.10            0.15                      1605            356.70           359.40            0.75             0.85
1405            556.20           559.80            0.00            0.35                      1610            351.70           354.50            0.75             0.90
1410            551.20           554.80            0.05            0.40                      1615            346.70           349.50            0.80             0.90
1415            546.20           549.80            0.00            0.40                      1620            341.80           344.50            0.80             0.95
1420            541.20           544.80            0.05            0.40                      1625            336.80           339.50            0.85             0.95
1425            536.30           539.80            0.15            0.20                      1630            331.80           334.60            0.90             1.00
Maturity  breakdown     (residual maturity)
More   than 1   More  than  3
Up  to 1       and  up  to 3   months   and
Total          month          months          up to 1 year
1. Foreign currency  loans, securities, and deposits                                        0              0              0              0
—outflows   (-)                                                 Principal                   0              0              0              0
Interest                    0              0              0              0
—inflows  (+)                                                   Principal
Interest
2. Aggregate   short and long positions in forwards  and futures in foreign
currencies  vis-à-vis the domestic  currency (including the forward  leg of            300            300               0              0
currency  swaps)
(a) Short positions ( - )                                                                 0              0              0              0
(b) Long  positions (+)                                                                300            300               0              0
3. Other  (specify)                                                                      -6             -6              0              0
—outflows   related to repos (-)                                                          0              0              0              0
—inflows   related to reverse repos (+)
—trade   credit (-)
—trade   credit (+)
—other   accounts  payable  (-)                                                          -6             -6              0              0
—other   accounts  receivable (+)
g  White
g  Asian                                                    Osteopathic          Allopathic
g  Hispanic/Latino                                              (2013)              (2013)
g  Black/                   White                                67%                 56%
African American         Asian                                20%                 21%
g  Two or More Races        Hispanic/Latino                      4%                  4%
g  Nonresident Alien
g  American Indian          Black/African   American             3%                  6%
& Alaska Native          Other/Multi-Race                     4%                  12%
g  Pacific Islander         Unknown                              2%                  1%
g  Unknown
Osteopathic         Allopathic
(2014)              (2014)
Men                       56%                53%
Women                     44%                47%
# Split   Polarity         Feature               Source
55          0.17            people         press release
54          0.30            years               abstract
50          0.13           evidence        press release
39          0.34            Nature               journal
38          0.52             zika                   title
33          0.14            planet         press release
33          0.40      American  Medical        publisher
Association
33          0.09           humans          press release
31          -0.01          patients             abstract
30          -0.22          protein         press release
30          0.33              95                abstract
29          -0.03          patients        press release
28          0.23       published today     press release
27          0.12            study          press release
27          0.13            years          press release
26          0.19           percent         press release
25          0.29         consumption       press release
25          0.36            foods          press release
24          0.13            fossil         press release
23          -0.25          proteins        press release
Weight               Feature                     Source
0.8226                  fish               press release
0.8236                  fat                press release
0.8307               screening                  abstract
0.8803               quantum               press release
0.9044               detection                      title
0.9616           Project HOPE    -             publisher
The  People-to-People
Health  Foundation,  Inc.
0.9646                 early                        title
1.0459     American   Chemical  Society        publisher
1.1415                 time                         title
1.2791       Oxford  University  Press         publisher
-1.1910               protein                       title
-1.0599               protein              press release
-0.9404              medicine                       title
-0.9334                 cell                        title
-0.9287             mechanism                       title
-0.8788             expression                      title
-0.8500             expression                  abstract
-0.8041                genes               press release
-0.8025              following                      title
-0.7689               domain                        title
Near  term                        Midpoint                      Contribution               Near term                        Midpoint                       Contribution
Strike       Option  Type         Price          Delta-K         by Strike                 Strike       Option  Type         Price         Delta-K         by Strike
1370             Put             0.200             5          0.0000005328                 1275             Put             0.075            50          0.0000023069
1375             Put             0.125             5          0.0000003306                 1325             Put             0.150            37.5        0.0000032041
1380             Put             0.150             5          0.0000003938                 1350             Put             0.150            25          0.0000020577
1385             Put             0.225             5          0.0000005865                 1375             Put             0.175            25          0.0000023141
1390             Put             0.225             5          0.0000005823                 1400             Put             0.200            25          0.0000025511
1395             Put             0.125             5          0.0000003212                 1425             Put             0.250            25          0.0000030779
1400             Put             0.125             7.5        0.0000004783                 1450             Put             0.300            25          0.0000035673
1410             Put             0.225             10         0.0000011318                 1475             Put             0.350            25          0.0000040219
1420             Put             0.225             7.5        0.0000008369                 1500             Put             0.400            17.5        0.0000031112
1425             Put             0.175             5          0.0000004309                 1510             Put             0.425            10          0.0000018640
1430             Put             0.225             5          0.0000005502                 1520             Put             0.450            7.5         0.0000014608
1435             Put             0.275             5          0.0000006677                 1525             Put             0.475             5          0.0000010213
1440             Put             0.175             5          0.0000004220                 1530             Put             0.500            7.5         0.0000016020
1445             Put             0.225             5          0.0000005388                 1540             Put             0.525            10          0.0000022138
1450             Put             0.200             5          0.0000004756                 1550             Put             0.550            7.5         0.0000017170
1455             Put             0.250             5          0.0000005905                 1555             Put             0.575             5          0.0000011890
1460             Put             0.250             5          0.0000005864                 1560             Put             0.600             5          0.0000012328
1465             Put             0.250             5          0.0000005824                 1565             Put             0.625             5          0.0000012759
1470             Put             0.250             5          0.0000005785                 1570             Put             0.650             5          0.0000013185
1475             Put             0.200             5          0.0000004596                 1575             Put             0.675             5          0.0000013606
1480             Put             0.250             5          0.0000005707                 1580             Put             0.675             5          0.0000013520
1485             Put             0.350             5          0.0000007936                 1585             Put             0.700             5          0.0000013932
1490             Put             0.175             5          0.0000003941                 1590             Put             0.725             5          0.0000014339
1495             Put             0.275             5          0.0000006152                 1595             Put             0.750             5          0.0000014741
1500             Put             0.325             5          0.0000007222                 1600             Put             0.775             5          0.0000015137
1505             Put             0.325             5          0.0000007174                 1605             Put             0.800             5          0.0000015528
1510             Put             0.300             5          0.0000006579                 1610             Put             0.825             5          0.0000015914
1515             Put             0.300             5          0.0000006535                 1615             Put             0.850             5          0.0000016295
1520             Put             0.350             5          0.0000007575                 1620             Put             0.875             5          0.0000016671
1525             Put             0.350             5          0.0000007525                 1625             Put             0.900             5          0.0000017042
1530             Put             0.325             5          0.0000006942                 1630             Put             0.950             5          0.0000017878
1535             Put             0.375             5          0.0000007958                 1635             Put             0.975             5          0.0000018237
1540             Put             0.375             5          0.0000007906                 1640             Put             1.000             5          0.0000018591
1545             Put             0.375             5          0.0000007855                 1645             Put             1.025             5          0.0000018940
1550             Put             0.500             5          0.0000010406                 1650             Put             1.075             5          0.0000019743
1555             Put             0.425             5          0.0000008788                 1655             Put             1.100             5          0.0000020081
1560             Put             0.425             5          0.0000008732                 1660             Put             1.150             5          0.0000020867
1565             Put             0.425             5          0.0000008676                 1665             Put             1.200             5          0.0000021644
1570             Put             0.475             5          0.0000009635                 1670             Put             1.225             5          0.0000021963
1575             Put             0.550             5          0.0000011086                 1675             Put             1.275             5          0.0000022723
1580             Put             0.525             5          0.0000010515                 1680             Put             1.325             5          0.0000023474
1585             Put             0.525             5          0.0000010449                 1685             Put             1.375             5          0.0000024215
1590             Put             0.525             5          0.0000010384                 1690             Put             1.425             5          0.0000024947
1595             Put             0.525             5          0.0000010319                 1695             Put             1.475             5          0.0000025670
1600             Put             0.675             5          0.0000013184                 1700             Put             1.525             5          0.0000026385
1605             Put             0.575             5          0.0000011161                 1705             Put             1.600             5          0.0000027520
1610             Put             0.625             5          0.0000012056                 1710             Put             1.675             5          0.0000028642
1615             Put             0.625             5          0.0000011982                 1715             Put             1.725             5          0.0000029325
Mortar         Type         Portland            Masonry    Coment   or               Hydrated   Lime                 Aggregate   Ratio
Cement   or             Mortar  Cement                     or Lime  Putty              (measured    in Damp,
Blended                                                                                Loose  Conditions
Cements             M          s        N
M               1              _—        _—        _                        4
5               1              ane       aoe       _                        Mito 4
EEE
Cement-Lime
N               1              =         =         |                  over 4to  14
oO               1              —         —_        —                 over 1!  to 24
:                                         Not less than 24
M               1              —         _          1                      _—                    and  not more  than 3
times  the sum  of the
Ml                                                        j
_                1        _—        —      |                =                     separate  volumes   of
Masonry                                                                      |                                     cementiious   materials
Cement             =              4               =         —         %                       _
or
Mortar            $             3s               =          i        ae                      =
Cement                                                                       j
N              —               —         —          1                      =
oO              =               =         =          1                      =
Description                 HCPCS                 Description
Bortezomib   injection                J9230       Mechlorethamine    hcl inj
Brentuximab   vedotin  inj            J9245       Inj melphalan  hydrochl  50 MG
Cabazitaxel  injection                J9250       Methotrexate   sodium  inj
Carboplatin  injection                J9260       Methotrexate   sodium  inj
Injection, carfilzomib, 1 mg          J9261       Nelarabine  injection
Carmustine   injection                J9262       Inj, omacetaxine  mep,  0.01mg
Cetuximab    injection                J9263       Oxaliplatin
Cisplatin 10 MG   injection           J9264       Paclitaxel protein bound
Cisplatin 50 MG   injection           J9265       Paclitaxel injection
Inj cladribine per 1 MG               J9266       Pegaspargase    injection
Cyclophosphamide     100  MG  inj     J9267       Injection, paclitaxel, 1 mg
Cyclophosphamide     200  MG  inj     J9268       Pentostatin  injection
Cyclophosphamide     500  MG  inj     J9270       Plicamycin  (mithramycin)  inj
Cyclophosphamide     1.0 grm  inj     J9271       Injection, pembrolizumab,   1 mg
Cyclophosphamide     2.0 grm  inj     J9280       Mitomycin  injection
Cyclophosphamide     lyophilized      J9290       Mitomycin  20  MG  inj
Cyclophosphamide     lyophilized      J9291       Mitomycin  40  MG  inj
Cyclophosphamide     lyophilized      J9293       Mitoxantrone  hydrochl  / 5 MG
Nutrient               Biologic       Val./reproduc     Coef      Details
tissue
Vitamin  D: D25        Plasma         Validity          0.35      Correlation between  FFQ  estimate of vit D intake (including supplements) with
(OH)D                                                             plasma  D25 (OH)D   (n=139). Correlation excluding supplement  users: r=0.25
(Willett, p 199)
0.18      Cross-sectional correlation between dietary intake of nutrients and biochemical
markers in UK  pre-school child study in females (n=350). In males (n=365)
r=0.06 (Margetts, table 7.9b).
Serum          Validity          0.24      Correlation between  estimated vit D intake from food and supplements (based
on 24 h recall) and serum D25 (OH)D   (n=373  healthy women).  Food  only:
r=0.11 (Willett, p 199).
Vitamin  C             Plasma         Validity          0.43      Unadjusted  correlation between questionnaire-derived dietary ascorbic acid
intake and plasma ascorbic acid concentration in a heterogeneous population.
Diet only: r=38 (Table 9.1). Correlation is 0.31 for leukocyte ascorbic acid
concentration.(Willett, p 200)
Reproducibility   0.28      Repeated  measures in men  obtained 6 years apart (Willett, p 201)
Validity          0.43      Cross-sectional correlation between dietary intake of nutrients and biochemical
markers in UK  pre-school child study in males (n=369). In females (n=354)
r=0.39 (Margetts, table 7.9b).
Serum          Validity          0.55      Correlation between  food-frequency questionnaire estimate of vit C intake and
serum  vit C values (in smokers) in 196 men in Scotland (adjusted for total
energy intake, BMI  and serum  cholesterol level). Non-smokers: 0.58 (Willett, p
200/201)
Leukocyte      Validity          0.49      Correlation between  one week  of intake data and a single leukocyte ascorbate
measurement   for men. For women:  r=0.36. Nutrition survey of elderly in UK
(Margetts, p 211)
Vitamin  B6            Plasma         Validity          0.37      Correlation between  B6 and plasma  pyridoxal phosphate levels in 280 healthy
Urinary        Validity          -         men  =0.37 (Willett p203)
Folacin                Serum          Validity          0.56      Correlation of 0.56 in Framington Heart study 385 subjects (serum)
Erythrocyte                      0.51      Correlation in 19 elderly subjects (erythrocyte) (Willet p204)
Magnesium              Serum          Validity          0.27      Correlation between  intake with supplements 0.27 in 139 men  and 0.15 without
supplements  (Willett p211)
Drug  Name  (Brand Name)                     Biomarker(s)                    Indication(s)
Oncology  (cont.)
74      Exemestane   (Aromasin®)                     ESR1; PGR                       Breast cancer
75      5-Fluorouracil (5-FU) (Efudex®)              DPYD                            Multiple cancers
76      Fulvestrant (Faslodex®)                      ESR1; PGR                       Breast cancer
77      Gefitinib (Iressa®)                          EGFR                            Non-small  cell lung cancer
78      Imatinib (Gleevec®)                          BCR-ABL;   PDGFRB;  KIT;        Multiple cancers,
FIP1L1-PDGFRA                   myelodysplastic syndrome
79      Irinotecan (Camptosar®)                      UGT1A1                          Colon  cancer, small cell lung
cancer
80      Lapatinib (Tykerb®)                          ERBB2;  HLA-DQA1;               Breast cancer
HLA-DRB1
81      Lenalidomide  (Revlimid®)                    Del (5q)                        Multiple myeloma,  mantle cell
lymphoma,   myelodysplastic
syndrome
82      Letrozole (Femara®)                          ESR1; PGR                       Breast cancer
83      Mercaptopurine   (Purinethol®)               TPMT                            Acute  lymphocytic leukemia,
chronic myeloid leukemia,
Crohn's disease, and ulcerative
colitis
84      Nilotinib (Tasigna®)                         UGT1A1;  BCR-ABL1               Chronic  myelogenous  leukemia
85      Obinutuzumab   (Gazyva®)                     MS4A1                           Chronic  lymphocytic leukemia,
follicular lymphoma
86      Omacetaxine   mepesuccinate  (Synribo®)      BCR-ABL1                        Chronic  myeloid leukemia
87      Panitumumab   (Vectibix®)                    EGFR;  KRAS                     Colon  cancer
88      Pemetrexed   (Alimta®)                       TS                              Lung  cancer
89      Pertuzumab   (Perjeta®)                      ERBB2                           Breast cancer
Platinum Therapies
90      Carboplatin                                  ERCC1                           Ovarian cancer
91      Cisplatin                                    TPMT                            Multiple cancers
92      Oxaliplatin                                  ERCC1                           Colorectal cancer
93      Nedaplatin                                   ERCC1                           Multiple cancers
94      Triplatin tetranitrate                       ERCC1                           Multiple cancers
95      Satraplatin                                  ERCC1                           Multiple cancers
ASSESSMEnT                                    inTERvEnTion
Cancer  treatment plan            Research-based  education, dispel
myths, and provide  the evidence for
CAM
Cancer  type and stage            Research-based  education, symptom
management,   and  address psycho-
logical issues
Chronic health issues and         Symptom   management    and address
troubling side effects, such as   psychological issues
pain, fatigue, and hot flashes
Cultural and community   CAM      Research-based  education, dispel
use and  beliefs                  myths, and provide  the evidence for
CAM
Disease prognosis                 Research-based  education, symptom
management,   and  address psycho-
